[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 351
1. Kang JH, Katayama Y, Han A, Shigaki S, Oishi J, Kawamura K, Toita R, Han XM, Mori T, Niidome T: Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor. J Am Soc Mass Spectrom; 2007 Jan;18(1):106-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor.
  • A novel mass spectrometry-based assay system for determining protein kinase activity employing mass-tagged substrate peptide probes was used for the diagnosis of tumors.
  • The phosphorylation ratio for the reaction of the H-type peptide probe with the tumor tissue lysate (B16 melanoma) was more than three times higher than that of the D type peptide probe with the normal skin tissue lysate.
  • These results show that the novel assay system for detecting protein kinase activity using mass-tag technology can be a simple and useful means to profile protein kinase activity for cell or tissue lysate samples, and can be applied to the diagnosis of tumors.
  • [MeSH-major] Melanoma, Experimental / diagnosis. Peptides / chemistry. Protein Kinases / analysis. Skin Neoplasms / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Mass Spectrom. 2005 Apr;16(4):482-90 [15792717.001]
  • [Cites] Crit Rev Oncog. 1994;5(5):429-50 [8519807.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):161-7 [9069266.001]
  • [Cites] Biochem J. 1992 Apr 1;283 ( Pt 1):159-64 [1567363.001]
  • [Cites] Endocr Relat Cancer. 2003 Sep;10(3):389-96 [14503915.001]
  • [Cites] Anal Biochem. 2005 May 1;340(1):165-70 [15802142.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):3979-85 [15987100.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):847-50 [15012979.001]
  • [Cites] Biochem J. 2002 Sep 15;366(Pt 3):977-81 [12119045.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):39-51 [15023349.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Jun;16(6):940-7 [15907708.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):7845-51 [16351129.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):287-300 [15986138.001]
  • [Cites] Biochem J. 1993 Sep 1;294 ( Pt 2):335-7 [8373348.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):85-9 [15057036.001]
  • [Cites] Biomacromolecules. 2002 Sep-Oct;3(5):905-9 [12217034.001]
  • [Cites] Curr Opin Cell Biol. 1990 Apr;2(2):192-7 [2194521.001]
  • [Cites] J Control Release. 2006 Jan 10;110(2):431-6 [16309776.001]
  • [Cites] Biochem J. 1993 Apr 15;291 ( Pt 2):329-43 [8484714.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Dec;16(12):2027-38 [16253516.001]
  • (PMID = 17046276.001).
  • [ISSN] 1044-0305
  • [Journal-full-title] Journal of the American Society for Mass Spectrometry
  • [ISO-abbreviation] J. Am. Soc. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Maleimides; 0 / Peptides; 125313-65-7 / Ro 31-7549; EC 2.7.- / Protein Kinases; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


2. Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG: A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme. Mol Cell Proteomics; 2009 Oct;8(10):2308-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RhoA controls changes in cell morphology and invasion associated with cancer phenotypes.
  • Cell lines derived from melanoma tumors at varying stages revealed that RhoA is selectively activated in cells of metastatic origin.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]
  • [Cites] Mol Pharmacol. 1997 Nov;52(5):903-11 [9351982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3726-30 [9520434.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):132-43 [9833774.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 20):3583-90 [11707510.001]
  • [Cites] J Invest Dermatol. 2006 Apr;126(4):862-8 [16470169.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):136-43 [10559899.001]
  • [Cites] J Neurobiol. 2000 Aug;44(2):126-44 [10934317.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Methods Enzymol. 2000;325:264-72 [11036609.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2112-21 [11360195.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Nat Cell Biol. 2001 Aug;3(8):723-9 [11483957.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E97-100 [11944043.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15 [12398996.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8 [12518064.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):133-42 [12635176.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):861-70 [12808121.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):711-9 [12844144.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]
  • [Cites] Science. 2003 Oct 10;302(5643):286-90 [14551435.001]
  • [Cites] J Biochem. 2003 Sep;134(3):309-13 [14561714.001]
  • [Cites] Biochemistry. 2004 Jan 13;43(1):9-18 [14705926.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):154-61 [14743221.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):6196-203 [14645234.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1192-200 [14871999.001]
  • [Cites] Trends Plant Sci. 2004 May;9(5):221-8 [15130547.001]
  • [Cites] BMC Microbiol. 2004 Mar 4;4:9 [15102328.001]
  • [Cites] Methods Mol Biol. 2004;284:37-49 [15173607.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):37087-94 [15215245.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7928-46 [15489911.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] In Vitro. 1979 May;15(5):342-50 [478563.001]
  • [Cites] J Biol Chem. 1983 Jun 10;258(11):6717-20 [6853500.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):283-9 [3856042.001]
  • [Cites] J Biol Chem. 1988 Jul 15;263(20):9598-606 [2838472.001]
  • [Cites] Oncogene. 1995 Mar 2;10(5):827-33 [7898924.001]
  • [Cites] J Virol. 1995 Jun;69(6):3920-3 [7745747.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1083-90 [8640765.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]
  • [Cites] Mol Cell Proteomics. 2006 Aug;5(8):1359-67 [16644720.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21477-86 [17548352.001]
  • [Cites] Protein Sci. 2008 Jan;17(1):126-35 [18156470.001]
  • [Cites] Cell. 2008 Oct 31;135(3):510-23 [18984162.001]
  • [Cites] J Cell Biochem. 2009 Feb 1;106(2):210-9 [19097084.001]
  • [Cites] Science. 1996 Jul 12;273(5272):245-8 [8662509.001]
  • (PMID = 19620624.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / F32 CA105796; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32-GM008759; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / P50-CA058187; United States / NCI NIH HHS / CA / F32 CA112847; United States / NCI NIH HHS / CA / F32-CA112847; United States / NIAID NIH HHS / AI / R01-AI060841; United States / NCI NIH HHS / CA / F32-CA105796; United States / NCI NIH HHS / CA / R01 CA126240; United States / NIAID NIH HHS / AI / R01 AI060841
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; AE28F7PNPL / Methionine; EC 3.6.5.2 / rhoA GTP-Binding Protein; EC 5.3.1.- / Aldose-Ketose Isomerases; EC 5.3.1.23 / MRDI protein, human
  • [Other-IDs] NLM/ PMC2758758
  •  go-up   go-down


3. Usaj M, Trontelj K, Miklavcic D, Kanduser M: Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells. J Membr Biol; 2010 Jul;236(1):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Mar 15;302(2):213-9 [11878799.001]
  • [Cites] J Immunol Methods. 1987 Jun 26;100(1-2):5-40 [3298441.001]
  • [Cites] Biochemistry. 1995 Jul 11;34(27):8520-32 [7612594.001]
  • [Cites] Bioelectrochemistry. 2004 Jun;63(1-2):327-32 [15110297.001]
  • [Cites] J Immunol Methods. 2008 Jul 31;336(2):142-51 [18514220.001]
  • [Cites] Plant Physiol. 1988 Jun;87(2):389-94 [16666152.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jul;9(7):543-56 [18496517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7132-6 [3463955.001]
  • [Cites] Radiol Oncol. 2010 Mar;44(1):34-41 [22933889.001]
  • [Cites] Hybridoma. 1988 Oct;7(5):505-18 [3198135.001]
  • [Cites] Cancer Immunol Immunother. 1994 Nov;39(5):342-5 [7987867.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C390-400 [17537804.001]
  • [Cites] IEEE Trans Biomed Eng. 2009 May;56(5):1491-501 [19203876.001]
  • [Cites] Biophys J. 1999 Apr;76(4):2090-8 [10096904.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):829-39 [16780801.001]
  • [Cites] Cancer Immun. 2002 Nov 07;2:15 [12747760.001]
  • [Cites] Anal Biochem. 1986 Nov 15;159(1):109-13 [3812988.001]
  • [Cites] Nature. 1976 Jul 1;262(5563):52-4 [180426.001]
  • [Cites] J Membr Biol. 2005 Aug;206(3):187-201 [16456714.001]
  • [Cites] Methods Mol Biol. 1995;48:355-63 [8528407.001]
  • [Cites] Biochim Biophys Acta. 1982 Nov 30;694(3):227-77 [6758848.001]
  • [Cites] J Membr Biol. 1993 Feb;132(1):27-40 [8459447.001]
  • [Cites] Exp Cell Res. 1984 Feb;150(2):477-82 [6692859.001]
  • [Cites] J Membr Biol. 2009 May;229(1):11-8 [19418087.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):431-42 [1808197.001]
  • [Cites] Bioelectrochemistry. 2008 Nov;74(1):124-9 [18667367.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 13;314(3):717-23 [14741694.001]
  • [Cites] Biophys J. 1998 Jun;74(6):3015-22 [9635756.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 17;1500(3):265-79 [10699368.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Oct 15;140(1):258-66 [3778446.001]
  • [Cites] Biophys J. 1991 May;59(5):1074-84 [1868154.001]
  • [Cites] Biochim Biophys Acta. 2008 Feb;1778(2):483-90 [17996722.001]
  • [Cites] FEBS Lett. 1985 Mar 25;182(2):278-80 [3979550.001]
  • [Cites] Biophys J. 1994 Oct;67(4):1574-81 [7819489.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 15;1524(2-3):118-30 [11113558.001]
  • [Cites] Methods Enzymol. 1993;220:174-96 [8350753.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3125-30 [19661325.001]
  • [Cites] Biochim Biophys Acta. 1986 Jun 13;858(1):206-16 [3707962.001]
  • [Cites] J Immunol Methods. 1990 Nov 6;134(1):35-42 [2172386.001]
  • [Cites] Eur J Biochem. 1989 Jan 15;179(1):109-15 [2645133.001]
  • [Cites] Science. 1982 Apr 30;216(4545):537-8 [7071601.001]
  • [Cites] Biochemistry. 1990 May 15;29(19):4561-7 [2372540.001]
  • [Cites] Biochim Biophys Acta. 1989 Jun 6;981(2):295-302 [2567186.001]
  • [Cites] Biochim Biophys Acta. 1990 May 16;1034(2):125-31 [2354188.001]
  • [Cites] Biochim Biophys Acta. 1984 Sep 5;775(3):446-8 [6466684.001]
  • [Cites] J Membr Biol. 1985;85(3):269-80 [3897548.001]
  • [Cites] J Cell Biol. 1986 Apr;102(4):1358-62 [3958050.001]
  • [Cites] AAPS PharmSci. 2002;4(4):E21 [12645993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2715-8 [10688917.001]
  • [Cites] Biochim Biophys Acta. 1989 Jul 24;983(1):42-50 [2758049.001]
  • [Cites] Mol Biotechnol. 2009 Oct;43(2):167-76 [19562526.001]
  • [Cites] Eur Biophys J. 2006 Feb;35(3):196-204 [16215750.001]
  • [Cites] Bioelectrochemistry. 2004 Apr;62(1):73-82 [14990328.001]
  • [Cites] J Immunol. 1979 Jun;122(6):2498-504 [312871.001]
  • [Cites] Biophys J. 1998 Apr;74(4):1889-98 [9545050.001]
  • [Cites] Biochim Biophys Acta. 1989 Nov 3;985(3):334-8 [2804114.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 May;132(5):755-64 [15886631.001]
  • [Cites] Clin Immunol. 2002 Jul;104(1):14-20 [12139943.001]
  • [Cites] Biophys J. 1992 Mar;61(3):810-5 [1504251.001]
  • [Cites] Cancer Immunol Immunother. 2002 Sep;51(7):367-75 [12192536.001]
  • [Cites] Mol Biotechnol. 2009 Mar;41(3):286-95 [19016008.001]
  • [Cites] FEBS Lett. 2007 May 22;581(11):2181-93 [17395182.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):37-48 [17241099.001]
  • [Cites] Biochim Biophys Acta. 1993 Nov 7;1152(2):207-18 [8218321.001]
  • [Cites] J Med Microbiol. 2007 Jun;56(Pt 6):733-7 [17510256.001]
  • (PMID = 20628737.001).
  • [ISSN] 1432-1424
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ito T, Koyama Y, Otsuka M: Analysis of the surface structure of DNA/polycation/hyaluronic acid ternary complex by Raman microscopy. J Pharm Biomed Anal; 2010 Jan 5;51(1):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Cell Line, Tumor. Freeze Drying. Gene Expression Regulation. Hyaluronic Acid / chemistry. Melanoma, Experimental. Mice. Plasmids. Polyethyleneimine / chemistry

  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692196.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-98-6 / Polyethyleneimine; 9004-61-9 / Hyaluronic Acid; 9007-49-2 / DNA
  •  go-up   go-down


5. Kakutani K, Doita M, Nishida K, Miyamoto H, Kurosaka M: Radiculopathy due to malignant melanoma in the sacrum with unknown primary site. Eur Spine J; 2008 Sep;17 Suppl 2:S271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.
  • Melanoma is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.
  • To report a very rare case of malignant melanoma in the sacrum with unknown primary origin.
  • The pathological diagnosis was malignant melanoma.
  • No obvious primary malignant melanoma was detected on the skin surface, on the oral or anal mucosa, or in the fundus oculi.
  • However the patient died nine months after initial diagnosis.
  • Malignant melanoma in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.
  • The melanoma could have been a metastatic tumor of the sacrum, although the primary site was not detected.
  • The incidence of primary melanoma is increasing faster than any other cancer.
  • Thus treatment of patients with spinal metastasis of melanoma is an important challenge for orthopedic surgeons.
  • [MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2000 Feb;10(1):78-80 [10711643.001]
  • [Cites] Cancer. 1997 May 1;79(9):1816-21 [9129001.001]
  • [Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]
  • [Cites] Oncology. 1972;26(2):265-70 [5049921.001]
  • [Cites] Cancer. 1972 Dec;30(6):1469-72 [4641758.001]
  • [Cites] Br J Surg. 1977 Nov;64(11):805-8 [588977.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]
  • [Cites] Ann Surg. 1980 Jan;191(1):98-104 [7352784.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]
  • [Cites] CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26 [2049635.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2579-81 [1933805.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6 [8588172.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Mar;77(3):307-9 [8600878.001]
  • [Cites] Br J Surg. 1967 Jul;54(7):651-8 [6026989.001]
  • (PMID = 18075762.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2525896
  •  go-up   go-down


6. Krafft C, Kirsch M, Beleites C, Schackert G, Salzer R: Methodology for fiber-optic Raman mapping and FTIR imaging of metastases in mouse brains. Anal Bioanal Chem; 2007 Oct;389(4):1133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases of malignant melanomas were induced by injecting tumor cells into the carotid artery of mice.
  • Possible reasons why metastatic cells of malignant melanomas were not identified in FTIR images are discussed.
  • [MeSH-minor] Animals. Automatic Data Processing. Brain / pathology. Cell Line, Tumor. Cluster Analysis. Female. Humans. Melanoma / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Optical Fibers. Spectroscopy, Fourier Transform Infrared / methods. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639353.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


7. Huang ZM, Li HZ, Xiao H, Ji ZG: [Melanoma adrenal metastasis: report of 3 cases and literature review]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanoma adrenal metastasis: report of 3 cases and literature review].
  • OBJECTIVE: To investigate the clinical diagnosis, treatment and prognosis of melanoma adrenal metastasis.
  • METHODS: A total of 48 cases of malignant melanoma from 1985 to 2007 were reviewed.
  • And three cases of melanoma adrenal metastasis were analyzed.
  • Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.
  • The other two cases underwent complete resection of melanoma metastasis.
  • When contralateral adrenal metastasis of melanoma was found 6 months later, left adrenalectomy laparoscopically was performed.
  • CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.
  • Patients with adrenal metastases from melanoma, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646432.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


8. Xu Y, Theobald V, Sung C, DePalma K, Atwater L, Seiger K, Perricone MA, Richards SM: Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med; 2008;6:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
  • BACKGROUND: HLA-A2 tetramer flow cytometry, IFNgamma real time RT-PCR and IFNgamma ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy.
  • HLA-A2 (A*0201) tetramer assay specific for gp100209(210M) and MART-126-35(27L), IFNgamma real time RT-PCR and ELISPOT methods were validated using tumor infiltrating lymphocyte cell lines (TIL) isolated from HLA-A2 melanoma patients.
  • A positive IFNgamma response (by RT-PCR and ELISPOT) to gp100 was demonstrated in PBMC from 3 melanoma patients.
  • These methods can be applied not only to cancer vaccines but to other therapeutic proteins as part of immunogenicity and safety analyses.
  • [MeSH-major] Antigens, Neoplasm / immunology. Enzyme-Linked Immunosorbent Assay / methods. Flow Cytometry / methods. HLA-A2 Antigen / immunology. Interferon-gamma / genetics. Melanoma / immunology. Membrane Glycoproteins / immunology. Neoplasm Proteins / immunology. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Calibration. Cell Line, Tumor. Humans. MART-1 Antigen. Reference Standards. Reproducibility of Results. Sensitivity and Specificity. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Dec 1;163(11):6292-300 [10570323.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1903-12 [15937544.001]
  • [Cites] J Pharm Biomed Anal. 2000 Jan;21(6):1249-73 [10708409.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):2287-96 [10925318.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44 [10944556.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6 [10950150.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6644-52 [11086110.001]
  • [Cites] Scand J Immunol. 2000 Dec;52(6):544-9 [11119258.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):376-88 [11920589.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1021-32 [11948109.001]
  • [Cites] J Immunother. 2002 Mar-Apr;25(2):97-138 [12074049.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):641-9 [12576430.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1301-12 [12684398.001]
  • [Cites] Cancer Immunol Immunother. 2004 Aug;53(8):715-22 [14997347.001]
  • [Cites] J Immunother. 2004 Jul-Aug;27(4):298-308 [15235391.001]
  • [Cites] J Immunol Methods. 2004 Aug;291(1-2):175-83 [15345315.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2227-34 [9973498.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):651-67 [10477550.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):705-15 [10477554.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] Methods Mol Biol. 2005;302:51-86 [15937345.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54 [10702485.001]
  • (PMID = 18945350.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2605437
  •  go-up   go-down


9. Parra RS, Almeida AL, Badiale GB, Moraes MM, Rocha JJ, Féres O: Melanoma of the anal canal. Clinics (Sao Paulo); 2010;65(10):1063-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2003 Jul-Aug;55(4):575-80 [12938606.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Ai Zheng. 2006 May;25(5):619-24 [16687086.001]
  • [Cites] Dis Colon Rectum. 2010 Apr;53(4):402-8 [20305438.001]
  • [Cites] Dis Colon Rectum. 2007 Jul;50(7):1004-10 [17468984.001]
  • [Cites] Trop Gastroenterol. 2007 Apr-Jun;28(2):76-8 [18050846.001]
  • [Cites] Zentralbl Chir. 2007 Dec;132(6):560-3 [18098086.001]
  • [Cites] Acta Chir Belg. 2008 Nov-Dec;108(6):756-8 [19241934.001]
  • [Cites] Eur J Surg Oncol. 2009 Jul;35(7):757-62 [18602790.001]
  • [Cites] Am Surg. 2006 Oct;72(10):917-20 [17058735.001]
  • (PMID = 21120314.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2972593
  •  go-up   go-down


10. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA: Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle; 2008 Aug;7(15):2392-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.
  • To identify C-MYC targets rate-limiting for proliferation of malignant melanoma, we stably inhibited C-MYC in several human metastatic melanoma lines via lentivirus-based shRNAs approximately to the levels detected in normal melanocytes.
  • C-MYC depletion also resulted in reduction in the amounts of deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. shRNA-mediated suppression of TS, IMPDH2 or PRPS2 resulted in the decrease of dNTP pools and retardation of the cell cycle progression of melanoma cells in a manner similar to that of C-MYC-depletion in those cells.
  • Reciprocally, concurrent overexpression of cDNAs for TS, IMPDH2 and PRPS2 delayed proliferative arrest caused by inhibition of C-MYC in melanoma cells.
  • Moreover, all three proteins express at higher levels in cells from several metastatic melanoma lines compared to normal melanocytes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2002 May;9(5):1031-44 [12049739.001]
  • [Cites] Mutat Res. 2002 Feb 20;499(2):197-211 [11827713.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Jun;3(3):163-75 [12769686.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):43893-6 [13679382.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):562-8 [15229481.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):733-7 [15386371.001]
  • [Cites] Cell Cycle. 2004 Aug;3(8):1005-7 [15280655.001]
  • [Cites] Anal Biochem. 1992 Oct;206(1):178-82 [1456431.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5216-24 [8395000.001]
  • [Cites] J Biol Chem. 1993 Dec 25;268(36):27277-85 [8262968.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2527-35 [7739536.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1039-48 [9342182.001]
  • [Cites] Pharmacol Ther. 1997 Oct-Dec;76(1-3):29-43 [9535167.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):220-4 [9988278.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Curr Med Chem. 1999 Jul;6(7):545-60 [10390600.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5321-33 [10508165.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):3875-80 [15736425.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2097-107 [15781619.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6294-304 [16024631.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:33-50 [16620024.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:51-62 [16620025.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:123-43 [16620027.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;302:145-67 [16620028.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):951-61 [16575405.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6598-605 [16818632.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):313-7 [16935001.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] EMBO Rep. 2007 Jan;8(1):70-6 [17159920.001]
  • [Cites] Oncogene. 2008 Mar 20;27(13):1905-15 [17906696.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5793-800 [12138190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2023-30 [11511533.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):105-13 [11511364.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;69:115-48 [11550793.001]
  • [CommentIn] Cell Cycle. 2008 Aug;7(15):2275-6 [18682683.001]
  • (PMID = 18677108.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083081; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA076581; United States / NCI NIH HHS / CA / R01-CA120244-A1; United States / NCI NIH HHS / CA / R01 CA120244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleotides; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 1.1.1.205 / IMP Dehydrogenase; EC 1.1.1.205 / IMPDH2 protein, human; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.6.1 / Ribose-Phosphate Pyrophosphokinase
  • [Other-IDs] NLM/ NIHMS486377; NLM/ PMC3744895
  •  go-up   go-down


11. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL: Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res; 2009 Nov 15;15(22):7029-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.
  • We sought to assess the effect of the addition of granulocyte/macrophage colony-stimulating factor (GM-CSF) to vaccination with a melanoma vaccine.
  • EXPERIMENTAL DESIGN: Ninety-seven patients with resected melanoma (stage II-IV) were enrolled, stratified by stage, and randomized to receive a cellular melanoma vaccine with or without GM-CSF.
  • The primary endpoint was delayed-type hypersensitivity (DTH) response to melanoma cells.
  • These immune changes were accompanied by an increase in early melanoma deaths and a trend toward worse survival with GM-CSF.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1996 Jul-Aug;46(4):225-44 [8673695.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):291-7 [10344219.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):720-31 [15613691.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3015-24 [16116189.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):237-45 [16047143.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):215-22 [17200357.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):226-32 [17116643.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]
  • [Cites] Eur J Haematol. 2007 Oct;79(4):292-6 [17655695.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):49-59 [18446337.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3239-46 [10866317.001]
  • [Cites] Am J Nephrol. 2000 Jan-Feb;20(1):53-6 [10644869.001]
  • [Cites] J Immunother. 2000 Mar-Apr;23(2):275-81 [10746554.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4169-80 [12377960.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4549-54 [12454111.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):186-200 [12491520.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):367-73 [12843799.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2447-56 [12855617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):64-72 [14593498.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6337-43 [15342423.001]
  • [Cites] J Immunol. 1988 Dec 1;141(11):3882-8 [3141506.001]
  • [Cites] Cancer Immunol Immunother. 1989;29(4):247-54 [2752392.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1131-45 [2001448.001]
  • [Cites] Blood. 1991 Aug 1;78(3):609-15 [1830497.001]
  • [Cites] J Clin Lab Anal. 1992;6(5):329-36 [1403355.001]
  • [Cites] Ann Surg. 1992 Oct;216(4):463-82 [1417196.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):512-22 [8460920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):853-7 [7509778.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2913-20 [9738558.001]
  • (PMID = 19903777.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA012582; United States / NCI NIH HHS / CA / R01 CA076489-05; United States / NCI NIH HHS / CA / CA12582; United States / NCI NIH HHS / CA / CA87071; United States / NCI NIH HHS / CA / CA076489-05; United States / NCI NIH HHS / CA / P01 CA012582-35; United States / NCI NIH HHS / CA / K08 CA087071; United States / NCI NIH HHS / CA / CA76489; United States / NCI NIH HHS / CA / R01 CA076489
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS219270; NLM/ PMC2920049
  •  go-up   go-down


12. Uchiyama S, Imamura N, Ohuchida J, Hiyoshi M, Nagano M, Marutsuka K, Akiyama Y, Chijiiwa K: Late recurrence of malignant melanoma in the duodenum. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1619-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence of malignant melanoma in the duodenum.
  • Melanoma is a malignancy originating from melanocytes.
  • The primary melanoma usually occurs on the skin, retina, anal canal or occasionally at other organs such as the esophagus, penis or vagina.
  • Although melanoma represents about one-third of all metastatic lesions in the gastrointestinal tract, metastasis of melanoma to the GI tract, detected radiologically or endoscopically, is relatively rare.
  • In most cases of malignant melanoma, recurrence and death occur within 10 years after treatment of the primary lesion.
  • We herein report a case showing a recurrence 17 years after extirpation of primary malignant melanoma in the foot.
  • A 65-year-old man, with a history of extirpation of a malignant melanoma in the sole of his foot 17 years before, presented with anorexia and severe anemia, and multiple duodenal tumors were pointed out with upper gastrointestinal endoscopy.
  • Histologic examination of the endoscopic biopsy specimen revealed proliferation of large polygonal cells with distinct nucleoli, and malignant melanoma was diagnosed immunohistochemically.
  • [MeSH-major] Duodenal Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102354.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CC chemokine receptor 9; 0 / Receptors, CCR
  •  go-up   go-down


13. Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP: Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs; 2007 Apr;25(2):107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.
  • Apomine, a novel bisphosphonate ester, has demonstrated anticancer activity in a variety of cancer cell lines; however, its mechanism of cytotoxicity is not well understood.
  • Previous work has demonstrated that Apomine induces cell death by activation of caspase-3 in several cancer cell types.
  • However, we have demonstrated that Apomine induces cell death in the A375 human melanoma cell line through a novel membrane-mediated mechanism that is independent of caspase-3 activation.
  • Interestingly, Apomine-mediated cell death in the A375 and UACC 3093 human melanoma cell lines is also independent of N-Ras farnesylation, which was a previously described mechanism of action for Apomine in other cancer cell types.
  • [MeSH-major] Antineoplastic Agents / toxicity. Apoptosis / drug effects. Cell Membrane / drug effects. Diphosphonates / toxicity. Melanoma / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1988 Nov 25;115(1):61-9 [3192948.001]
  • [Cites] Cancer Treat Rev. 2004 Nov;30(7):609-41 [15531395.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67 [15951237.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3468-74 [12429636.001]
  • [Cites] Cancer Lett. 2000 Apr 28;152(1):107-13 [10754212.001]
  • [Cites] Leukemia. 2003 Feb;17(2):451-7 [12592346.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):89-94 [16379038.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):772-9 [15737653.001]
  • [Cites] Int J Hyperthermia. 1989 May-Jun;5(3):329-40 [2498438.001]
  • [Cites] Anticancer Drugs. 1997 Mar;8(3):245-56 [9095329.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):3009-13 [1182696.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Sep;83(2):93-104 [7553595.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):240-6 [10733934.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74 [11459867.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):89-92 [9844599.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):362-70 [15737846.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):65-73 [15688405.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6465-73 [14627708.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] J Immunol Methods. 1983 Nov 25;64(3):313-20 [6199426.001]
  • [Cites] J Cell Physiol. 1984 Jan;118(1):27-33 [6418750.001]
  • [Cites] Cell Tissue Kinet. 1990 Nov;23(6):603-17 [2276175.001]
  • [Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80 [16181759.001]
  • [Cites] J Supramol Struct. 1976;4(1):127-32 [1256059.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Mar 1;163(2):195-202 [10698678.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1747-53 [10469620.001]
  • [Cites] Biochemistry. 2002 Nov 19;41(46):13698-704 [12427032.001]
  • [Cites] Nutr Cancer. 1998;31(2):111-8 [9770722.001]
  • (PMID = 17024575.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA27502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Diphosphonates; 0 / apomine; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; EC 3.6.5.2 / ras Proteins; VC2W18DGKR / Thymidine
  •  go-up   go-down


14. Andreu-Pérez P, Hernandez-Losa J, Moliné T, Gil R, Grueso J, Pujol A, Cortés J, Avila MA, Recio JA: Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer; 2010;10:265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth.
  • BACKGROUND: Melanoma is the most deadly form of skin cancer without effective treatment.
  • In this study we have assessed the therapeutic potential of MTA in melanoma treatment.
  • METHODS: To investigate the therapeutic potential of MTA we performed in vitro proliferation and viability assays using six different mouse and human melanoma cell lines wild type for RAS and BRAF or harboring different mutations in RAS pathway.
  • We also have tested its therapeutic capabilities in vivo in a xenograft mouse melanoma model and using variety of molecular techniques and tissue culture we investigated its anti-proliferative and pro-apoptotic properties.
  • RESULTS: In vitro experiments showed that MTA treatment inhibited melanoma cell proliferation and viability in a dose dependent manner, where BRAF mutant melanoma cell lines appear to be more sensitive.
  • CONCLUSIONS: MTA inhibits melanoma cell proliferation and in vivo tumor growth particularly in BRAF mutant melanoma cells.
  • These data reveal a naturally occurring drug potentially useful for melanoma treatment.
  • [MeSH-major] Adenosine / pharmacology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thionucleosides / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Adenosine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Jun;44(6):2297-301 [6426777.001]
  • [Cites] J Biol Chem. 1984 May 10;259(9):5465-71 [6425290.001]
  • [Cites] Exp Hematol. 1984 Dec;12(11):867-71 [6510486.001]
  • [Cites] Anal Biochem. 1986 Nov 15;159(1):109-13 [3812988.001]
  • [Cites] Cancer Res. 1987 Apr 1;47(7):1771-4 [3102048.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3830-4 [3474063.001]
  • [Cites] J Cell Physiol. 1987 Nov;133(2):372-6 [3119605.001]
  • [Cites] Biochim Biophys Acta. 1991 Mar 26;1088(3):365-72 [2015299.001]
  • [Cites] Mol Cell Biol. 1992 Jan;12(1):103-11 [1729592.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4244-9 [8440708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6489-93 [7604019.001]
  • [Cites] Exp Cell Res. 1998 May 1;240(2):282-92 [9597001.001]
  • [Cites] Arch Biochem Biophys. 1964 Jul 20;106:95-100 [14217209.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Ann Neurol. 2006 Sep;60(3):323-34 [16786535.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):207-18 [17631143.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21477-86 [17548352.001]
  • [Cites] J Cell Biochem. 2009 Feb 1;106(2):210-9 [19097084.001]
  • [Cites] PLoS One. 2009;4(3):e4771 [19274086.001]
  • [Cites] PLoS One. 2009;4(5):e5735 [19478948.001]
  • [Cites] Mol Pharmacol. 2009 Jul;76(1):192-200 [19372210.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1549-61 [19810100.001]
  • [Cites] Cell. 2001 Mar 9;104(5):731-41 [11257227.001]
  • [Cites] J Hepatol. 2001 Mar;34(3):386-94 [11322199.001]
  • [Cites] FASEB J. 2002 Jan;16(1):15-26 [11772932.001]
  • [Cites] Hepatology. 2002 Feb;35(2):274-80 [11826399.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1000-8 [11850817.001]
  • [Cites] Alcohol. 2002 Jul;27(3):193-8 [12163149.001]
  • [Cites] Mol Endocrinol. 2002 Sep;16(9):2008-18 [12198239.001]
  • [Cites] Hepatology. 2004 Apr;39(4):1088-98 [15057913.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4699-702 [6411330.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Oct 15;124(1):172-7 [6497877.001]
  • (PMID = 20529342.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ribosomal Protein S6; 0 / Thionucleosides; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; K72T3FS567 / Adenosine
  • [Other-IDs] NLM/ PMC2891639
  •  go-up   go-down


15. Celebi ME, Kingravi HA, Iyatomi H, Aslandogan YA, Stoecker WV, Moss RH, Malters JM, Grichnik JM, Marghoob AA, Rabinovitz HS, Menzies SW: Border detection in dermoscopy images using statistical region merging. Skin Res Technol; 2008 Aug;14(3):347-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: As a result of advances in skin imaging technology and the development of suitable image processing techniques, during the last decade, there has been a significant increase of interest in the computer-aided diagnosis of melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skin Res Technol. 2005 Feb;11(1):17-26 [15691255.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Nov;26(11):1452-8 [15521493.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):454-62 [17908199.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):286-91 [7887657.001]
  • [Cites] J Am Acad Dermatol. 1993 Oct;29(4):581-8 [8408794.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Feb;18(2):164-71 [10232673.001]
  • [Cites] Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89 [9890182.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):183-90 [16567974.001]
  • (PMID = 19159382.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R44 CA060294-02A2; United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / 2R44 CA-101639-02A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS317765; NLM/ PMC3160669
  •  go-up   go-down


16. Bauer GL, Praetorius C, Bergsteinsdóttir K, Hallsson JH, Gísladóttir BK, Schepsky A, Swing DA, O'Sullivan TN, Arnheiter H, Bismuth K, Debbache J, Fletcher C, Warming S, Copeland NG, Jenkins NA, Steingrímsson E: The role of MITF phosphorylation sites during coat color and eye development in mice analyzed by bacterial artificial chromosome transgene rescue. Genetics; 2009 Oct;183(2):581-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vertebrates, it regulates the development of several cell types including melanocytes and has also been shown to play an important role in melanoma.


17. Baron R, Zayats M, Willner I: Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: assays for the detection of neurotransmitters and of tyrosinase activity. Anal Chem; 2005 Mar 15;77(6):1566-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of tyrosinase activity is important for detecting melanoma cells and Parkinson disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762558.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 46627O600J / Levodopa; 7440-57-5 / Gold; EC 1.14.18.1 / Monophenol Monooxygenase; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


18. Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G: Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol; 2010 Mar 19;5(3):333-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.
  • In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and melanoma cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:33-57 [10872443.001]
  • [Cites] Science. 2006 Jan 27;311(5760):535-8 [16439663.001]
  • [Cites] Anal Biochem. 2000 Nov 15;286(2):257-64 [11067748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3226-31 [11248060.001]
  • [Cites] Arch Biochem Biophys. 2001 May 1;389(1):135-43 [11370664.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):259-71 [11943403.001]
  • [Cites] J Am Chem Soc. 2002 May 15;124(19):5256-7 [11996552.001]
  • [Cites] Biochemistry. 2003 Jul 1;42(25):7748-58 [12820884.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1952-62 [15128304.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] Curr Opin Biotechnol. 2004 Aug;15(4):291-7 [15296927.001]
  • [Cites] Biochemistry. 1970 Oct 27;9(22):4352-9 [5472710.001]
  • [Cites] Anal Biochem. 1989 Nov 1;182(2):319-26 [2610349.001]
  • [Cites] Arch Biochem Biophys. 1991 Apr;286(1):217-21 [1910285.001]
  • [Cites] Arch Biochem Biophys. 1994 Jul;312(1):31-7 [8031143.001]
  • [Cites] Biochemistry. 1997 Aug 12;36(32):9847-58 [9245417.001]
  • [Cites] Biochemistry. 1997 Aug 26;36(34):10558-65 [9265637.001]
  • [Cites] Biochemistry. 1998 Jun 9;37(23):8539-50 [9622506.001]
  • [Cites] Structure. 1999 Apr 15;7(4):435-48 [10196128.001]
  • [Cites] J Clin Pathol. 1961 Jul;14:418-24 [13688207.001]
  • [Cites] Biomol Eng. 2005 Jun;22(1-3):73-9 [15857786.001]
  • [Cites] Biochemistry. 2006 Jan 31;45(4):1313-20 [16430228.001]
  • [Cites] Biochemistry. 2006 Sep 5;45(35):10654-66 [16939217.001]
  • [Cites] Proteins. 2006 Nov 15;65(3):637-42 [16981206.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]
  • [Cites] BioDrugs. 2008;22(1):53-8 [18215091.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1700-6 [19089915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 16;106 Suppl 1:9995-10000 [19528653.001]
  • [ErratumIn] ACS Chem Biol. 2010 Aug 20;5(8):797
  • (PMID = 20050660.001).
  • [ISSN] 1554-8937
  • [Journal-full-title] ACS chemical biology
  • [ISO-abbreviation] ACS Chem. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 139059; United States / NCI NIH HHS / CA / R01 CA139059; United States / NCI NIH HHS / CA / CA139059-01; United States / NIBIB NIH HHS / EB / P30 EB009998; United States / NCI NIH HHS / CA / R01 CA139059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3G0H8C9362 / Cobalt; 42Z2K6ZL8P / Manganese; EC 3.5.3.1 / Arginase
  • [Other-IDs] NLM/ NIHMS170379; NLM/ PMC2842482
  •  go-up   go-down


19. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, Kelly K, Merlino G: Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene; 2010 Apr 22;29(16):2449-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous malignant melanoma is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy.
  • NRAS and BRAF mutations are rarely found in the same melanoma, suggesting that they may possess important overlapping oncogenic activities.
  • More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several malignant phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Genet. 2009 May;41(5):544-52 [19282848.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):5-7 [12150818.001]
  • [Cites] Genes Dev. 2002 Aug 15;16(16):2045-57 [12183360.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6724-30 [12438273.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3113-22 [12789288.001]
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):419-25 [12888294.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):800-6 [12856001.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2338-42 [15059882.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):171-83 [15324700.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2503-12 [2188091.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):810-6 [8631302.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3397-402 [9692547.001]
  • [Cites] Anal Biochem. 1999 Jun 1;270(2):207-19 [10334838.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):533-45 [15950903.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):745-9 [15951821.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7111-20 [16103060.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(2):727-34 [16382162.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):154-60 [16417231.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]
  • [Cites] Cell. 2006 Oct 6;127(1):157-70 [17018283.001]
  • [Cites] Curr Biol. 2006 Dec 19;16(24):2385-94 [17174914.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968-73 [17576930.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3803-13 [17606711.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7538-50 [17709381.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):8003-14 [17875936.001]
  • [Cites] Melanoma Res. 2007 Dec;17(6):410-2 [17992125.001]
  • [Cites] APMIS. 2007 Oct;115(10):1161-76 [18042149.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):133-40 [18219307.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 [18353141.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3364-72 [18227351.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):784-95 [18505964.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Apr;41(4):757-61 [18950730.001]
  • [ErratumIn] Oncogene. 2011 Apr 14;30(15):1850
  • (PMID = 20118982.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA BC008756-22; United States / Intramural NIH HHS / / ZIA BC008756-23; United States / Intramural NIH HHS / / Z99 CA999999; United Kingdom / Wellcome Trust / / 078327; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / ral Guanine Nucleotide Exchange Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS357536; NLM/ PMC3287039
  •  go-up   go-down


20. van't Riet M, Giard RW, de Wilt JH, Vles W: Melanoma of the anus disguised as hemorrhoids: surgical management illustrated by a case report. Dig Dis Sci; 2007 Jul;52(7):1745-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anus disguised as hemorrhoids: surgical management illustrated by a case report.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / surgery. Hemorrhoids / diagnosis. Melanoma / diagnosis. Melanoma / surgery
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Hemorrhoids.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):438-9 [15925823.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):121-3 [12942268.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):478-85 [1589984.001]
  • [Cites] Am Surg. 1993 Jul;59(7):400-4 [8323072.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1194-5 [8402131.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):866-74 [8076485.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • (PMID = 17415639.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1914244
  •  go-up   go-down


21. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J: Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol; 2006 May;168(5):1666-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.
  • The immune system recognizes diverse melanoma antigens.
  • Here, we have investigated 33 biopsies (eight primary and 25 metastases) from 24 melanoma patients (15-72 years old) and describe the correlation between the expression of galectin-3 or galectin-1 and the level of apoptosis of tumor-associated lymphocytes using immunohistochemistry and an in situ nick translation assay.
  • Considering the complex process of cancer immunoediting, various interacting factors must be considered.
  • [MeSH-major] Biomarkers / analysis. Biopsy. Galectin 1 / metabolism. Galectin 3 / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2004 Jun;63(6):636-43 [15140769.001]
  • [Cites] J Clin Invest. 1993 Mar;91(3):1183-90 [8450047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 [15381769.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):899-909 [10702407.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2331-4 [10946254.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3560-4 [10999744.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):5697-707 [11698442.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6852-7 [11724777.001]
  • [Cites] J Exp Med. 2002 May 20;195(10):1303-16 [12021310.001]
  • [Cites] Trends Immunol. 2002 Jun;23(6):313-20 [12072371.001]
  • [Cites] Glycobiology. 2002 Oct;12(10):127R-36R [12244068.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8221-5 [14678978.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8302-11 [14678989.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1602-11 [14734741.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4705-12 [14617626.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):241-51 [15050916.001]
  • [Cites] Exp Cell Res. 2004 May 1;295(2):315-29 [15093732.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4395-406 [15121858.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):736-9 [7501023.001]
  • [Cites] Circulation. 1996 Sep 15;94(6):1255-62 [8822977.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5272-6 [9393748.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):97-106 [9468337.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):443-7 [10384147.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):385-98 [10430627.001]
  • [Cites] Cell Death Differ. 2004 Dec;11(12):1277-86 [15297883.001]
  • [Cites] Am J Pathol. 2004 Dec;165(6):1853-63 [15579430.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):29-41 [15630413.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]
  • (PMID = 16651632.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Galectin 1; 0 / Galectin 3; 0 / LGALS1 protein, human
  • [Other-IDs] NLM/ PMC1606586
  •  go-up   go-down


22. Rizzi R, Mahata P, Mathieson L, Moscato P: Hierarchical clustering using the arithmetic-harmonic cut: complexity and experiments. PLoS One; 2010;5(12):e14067
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To this end, we implement a memetic algorithm for the problem and demonstrate the effectiveness of the arithmetic-harmonic cut on a number of datasets including a cancer type dataset and a corona virus dataset.
  • [MeSH-minor] Algorithms. Cell Line, Tumor. Cluster Analysis. Colonic Neoplasms / metabolism. Gene Expression Profiling. Humans. Leukemia / metabolism. Melanoma / metabolism. Models, Statistical. Models, Theoretical

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Evol Comput. 2000 Spring;8(1):61-91 [10753231.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2007 Nov;29(11):1944-57 [17848776.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1453-4 [14871861.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] BMC Bioinformatics. 2003 Sep 20;4:43 [14499005.001]
  • (PMID = 21151943.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2997101
  •  go-up   go-down


23. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res; 2010;29:132
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Lung Neoplasms / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] Hum Mutat. 2004 Apr;23(4):368-78 [15024731.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):207-12 [9056213.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1267-74 [9579832.001]
  • [Cites] Clin Chem. 1998 May;44(5):918-23 [9590362.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 15;27(16):e12 [10454649.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):557-8 [16595822.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):642-8 [16827805.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Chest. 2007 Jun;131(6):1628-34 [17565015.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):778-84 [17848912.001]
  • [Cites] Clin Chem. 2008 Apr;54(4):757-60 [18375489.001]
  • [Cites] Cancer Sci. 2008 May;99(5):929-35 [18325048.001]
  • [Cites] Nat Med. 2008 May;14(5):579-84 [18408729.001]
  • [Cites] Eur Respir J. 2009 Jun;33(6):1485-97 [19483050.001]
  • [Cites] Br J Cancer. 2009 Nov 17;101(10):1724-30 [19861964.001]
  • [Cites] Nat Rev Drug Discov. 2010 May;9(5):363-6 [20431568.001]
  • [Cites] Mol Med. 2002 May;8(5):227-37 [12359953.001]
  • [Cites] Pathol Res Pract. 1993 Feb;189(1):66-72 [8390645.001]
  • (PMID = 20925915.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2988723
  •  go-up   go-down


24. Björn E, Nygren Y, Nguyen TT, Ericson C, Nöjd M, Naredi P: Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry. Anal Biochem; 2007 Apr 1;363(1):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Samples of isolated DNA and exosome fractions from human ovarian (2008) and melanoma (T289) cancer cell lines were used.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Mass Spectrometry. Melanoma / metabolism. Ovarian Neoplasms / metabolism. Sensitivity and Specificity. Subcellular Fractions

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17286953.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Organoplatinum Compounds; 49DFR088MY / Platinum; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Piantanelli A, Maponi P, Scalise L, Serresi S, Cialabrini A, Basso A: Fractal characterisation of boundary irregularity in skin pigmented lesions. Med Biol Eng Comput; 2005 Jul;43(4):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although melanoma is one of the most aggressive tumours, early detection and a high rate of diagnostic accuracy, followed by timely excision, can allow complete recovery in melanoma patients.
  • This result is important for screening, as it can inform the decision to excise precociously malignant lesions or to avoid unnecessary removal of benign ones.
  • [MeSH-major] Fractals. Image Processing, Computer-Assisted / methods. Melanoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mech Ageing Dev. 2001 Sep 15;122(13):1461-75 [11470133.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):78-83 [10502430.001]
  • [Cites] Pathologica. 1995 Jun;87(3):310-7 [8570291.001]
  • [Cites] Med Image Anal. 2003 Mar;7(1):47-64 [12467721.001]
  • [Cites] Am J Dermatopathol. 1995 Aug;17(4):374-8 [8600802.001]
  • [Cites] Curr Eye Res. 1993 Jan;12(1):23-7 [8436007.001]
  • [Cites] Arch Dermatol. 1998 Dec;134(12):1563-70 [9875194.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):481-6 [12207587.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Aug;22(8):959-64 [12906250.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):174-82 [8685210.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3683-8 [10919633.001]
  • [Cites] J Telemed Telecare. 2000;6(3):132-7 [10912329.001]
  • [Cites] J Pathol. 1992 Apr;166(4):409-11 [1517895.001]
  • [Cites] J Biomed Eng. 1992 May;14(3):229-34 [1588780.001]
  • [Cites] Neurobiol Aging. 2002 Jan-Feb;23(1):23-6 [11755014.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):679-93 [12734496.001]
  • [Cites] Skin Res Technol. 1995 Nov;1(4):187-91 [27326721.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1236-41 [3815299.001]
  • [Cites] J Pathol. 1995 Sep;177(1):103-7 [7472773.001]
  • [Cites] Arch Dermatol. 1993 Feb;129(2):157-74 [8434973.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):270-6; quiz 277 [11358742.001]
  • [Cites] J Pathol. 1997 May;182(1):1-8 [9227334.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2002 May 29;357(1421):619-26 [12079523.001]
  • [Cites] Riv Biol. 2002 May-Aug;95(2):239-58 [12449683.001]
  • (PMID = 16255424.001).
  • [ISSN] 0140-0118
  • [Journal-full-title] Medical & biological engineering & computing
  • [ISO-abbreviation] Med Biol Eng Comput
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P: Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. Chin Med J (Engl); 2010 Mar 5;123(5):585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma.
  • BACKGROUND: Anorectal malignant melanoma was a rare disease with extremely poor prognosis.
  • The aim of this study was to explore the clinical characteristic, diagnosis and treatment strategies of anorectal malignant melanoma.
  • METHODS: The data of 57 patients with anorectal malignant melanoma was collected and retrospectively analyzed.
  • RESULTS: Rectal bleeding and anal mass were found to be common symptoms of anorectal malignant melanoma.
  • The preoperative diagnosis rate of anorectal malignant melanoma was 48.6%.
  • CONCLUSIONS: This study identified no survival advantage to abdominoperineal resection in treatment of anorectal malignant melanoma, and we propose that wide local excision could be considered as the initial treatment of choice.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367986.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ: Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem; 2008 Jan;56(1):57-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression in normal skin and non-melanoma skin tumors.
  • Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types of cancer and has been shown to facilitate tumorigenesis in vivo.
  • To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]
  • [Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]
  • [Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]
  • [Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]
  • [Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]
  • [Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]
  • [Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]
  • [Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]
  • [Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • (PMID = 17938278.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2323122
  •  go-up   go-down


28. Chang TM: Nanobiotechnological modification of hemoglobin and enzymes from this laboratory. Biochim Biophys Acta; 2008 Oct;1784(10):1435-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other approaches include a polyhemoglobin-fibrinogen that acts as an oxygen carrier with platelet-like activity, and a polyhemoglobin-tyrosinase to retard the growth of a fatal skin cancer, melanoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem. 2002 Apr;131(4):611-7 [11927000.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(5):481-9 [17922313.001]
  • [Cites] J Am Coll Surg. 2002 Oct;195(4):445-52; discussion 452-5 [12375748.001]
  • [Cites] Nat Rev Drug Discov. 2004 Feb;3(2):152-9 [15043006.001]
  • [Cites] Melanoma Res. 2004 Jun;14(3):197-202 [15179188.001]
  • [Cites] Anal Biochem. 1971 Apr;40(2):450-8 [5551554.001]
  • [Cites] Biochem Biophys Res Commun. 1971 Sep 17;44(6):1531-6 [5160711.001]
  • [Cites] J Bioeng. 1976 Nov;1(1):25-32 [1052520.001]
  • [Cites] Exp Hematol. 1980 May;8(5):584-92 [7461058.001]
  • [Cites] Methods Enzymol. 1985;112:195-203 [4046849.001]
  • [Cites] Trends Biochem Sci. 1989 Feb;14(2):42-4 [2650040.001]
  • [Cites] Biomater Artif Cells Immobilization Biotechnol. 1993;21(5):609-21 [8117850.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):889-93 [7994414.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):169-83 [8773737.001]
  • [Cites] Nat Biotechnol. 1998 Jul;16(7):667-71 [9661202.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Feb;288(2):665-70 [9918573.001]
  • [Cites] Science. 1964 Oct 23;146(3643):524-5 [14190240.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):11-8 [17364467.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):31-43 [17364469.001]
  • [Cites] Artif Cells Blood Substit Immobil Biotechnol. 2002 Jan;30(1):23-37 [12000224.001]
  • (PMID = 18565337.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] None / None / / 13745; Canada / Canadian Institutes of Health Research / / 13745
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Substitutes; 0 / Cross-Linking Reagents; 0 / Hemoglobins; 0 / Oxyhemoglobins; 0 / polyhemoglobin; 9001-32-5 / Fibrinogen; 9034-51-9 / Hemoglobin A; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ CAMS2513; NLM/ PMC3514548
  •  go-up   go-down


29. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG: Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell; 2009 Apr 10;34(1):115-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
  • Melanoma and other cancers harbor oncogenic mutations in the protein kinase B-Raf, which leads to constitutive activation and dysregulation of MAP kinase signaling.
  • In order to elucidate molecular determinants responsible for B-Raf control of cancer phenotypes, we present a method for phosphoprotein profiling, using negative ionization mass spectrometry to detect phosphopeptides based on their fragment ion signature caused by release of PO(3)(-).
  • Ninety phosphorylation events were regulated by oncogenic B-Raf signaling, based on their responses to treating melanoma cells with MKK1/2 inhibitor.
  • We investigated MINERVA/FAM129B, a target belonging to a protein family with unknown category and function, and established the importance of this protein and its MAP kinase-dependent phosphorylation in controlling melanoma cell invasion into three-dimensional collagen matrix.


30. Nedosekin DA, Shashkov EV, Galanzha EI, Hennings L, Zharov VP: Photothermal multispectral image cytometry for quantitative histology of nanoparticles and micrometastasis in intact, stained and selectively burned tissues. Cytometry A; 2010 Nov;77(11):1049-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using this tool, individual carbon nanotubes, gold nanorods, and melanoma cells with intrinsic melanin markers were identified in unstained (e.g. sentinel lymph nodes) and conventionally-stained tissues.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Society for Advancement of Cytometry.
  • [Cites] BMC Cell Biol. 2007;8 Suppl 1:S8 [17634098.001]
  • [Cites] Magn Reson Med. 2007 May;57(5):835-41 [17457873.001]
  • [Cites] Biosens Bioelectron. 2007 Nov 30;23(4):449-58 [17881213.001]
  • [Cites] Clin Chem. 2007 Nov;53(11):2002-9 [17890442.001]
  • [Cites] Small. 2008 Jan;4(1):153-9 [18081130.001]
  • [Cites] J Toxicol Sci. 2008 Feb;33(1):105-16 [18303189.001]
  • [Cites] Mol Pharm. 2008 Mar-Apr;5(2):316-27 [18217714.001]
  • [Cites] Environ Sci Technol. 2008 Aug 15;42(16):6264-70 [18767697.001]
  • [Cites] Cytometry A. 2008 Oct;73(10):884-94 [18677768.001]
  • [Cites] Nano Lett. 2008 Nov;8(11):3953-8 [18834183.001]
  • [Cites] Analyst. 2009 Mar;134(3):425-39 [19238274.001]
  • [Cites] Cytometry A. 2009 Apr;75(4):282-8 [19012320.001]
  • [Cites] J Biophotonics. 2009 Feb;2(1-2):91-103 [19343688.001]
  • [Cites] Nano Lett. 2009 Mar;9(3):1023-7 [19199447.001]
  • [Cites] Clin Chim Acta. 2009 May;403(1-2):1-8 [19361470.001]
  • [Cites] J Biomed Opt. 2009 Mar-Apr;14(2):021017 [19405730.001]
  • [Cites] J Biomech Eng. 2009 Jul;131(7):074519 [19640155.001]
  • [Cites] Ultrastruct Pathol. 2009 Jul-Aug;33(4):155-9 [19728231.001]
  • [Cites] J Biophotonics. 2009 Sep;2(8-9):528-39 [19743443.001]
  • [Cites] Photosynth Res. 2009 Aug-Sep;101(2-3):245-66 [19714478.001]
  • [Cites] Nat Nanotechnol. 2009 Oct;4(10):688-94 [19809462.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):7926-34 [19826056.001]
  • [Cites] J Mass Spectrom. 2009 Oct;44(10):1417-22 [19753579.001]
  • [Cites] Nature. 2009 Oct 22;461(7267):1105-9 [19847261.001]
  • [Cites] J R Soc Interface. 2010 Jan 6;7(42):49-59 [19324670.001]
  • [Cites] Nat Nanotechnol. 2009 Dec;4(12):855-60 [19915570.001]
  • [Cites] Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):353-9 [20049802.001]
  • [Cites] Mol Biosyst. 2010 Apr;6(4):641-7 [20237641.001]
  • [Cites] Radiology. 2010 May;255(2):442-50 [20413757.001]
  • [Cites] Chem Rev. 2010 May 12;110(5):2783-94 [20387910.001]
  • [Cites] Opt Express. 2010 Apr 12;18(8):8605-20 [20588705.001]
  • [Cites] Opt Express. 2010 Jul 5;18(14):14375-84 [20639922.001]
  • [Cites] Nature. 2010 Jul 29;466(7306):647-51 [20613725.001]
  • [Cites] ACS Nano. 2010 Jul 27;4(7):3689-96 [20550178.001]
  • [Cites] J Biophotonics. 2010 Dec;3(12):791-806 [20572284.001]
  • [Cites] Arch Toxicol. 2011 Jul;85(7):723-31 [20499226.001]
  • [Cites] Opt Lett. 2003 Aug 1;28(15):1314-6 [12906074.001]
  • [Cites] Biophys J. 2006 Jan 15;90(2):619-27 [16239330.001]
  • [Cites] Phys Chem Chem Phys. 2006 Aug 14;8(30):3486-95 [16871337.001]
  • [Cites] Histopathology. 2006 Oct;49(4):411-24 [16978205.001]
  • [Cites] Environ Health Perspect. 2007 Mar;115(3):377-82 [17431486.001]
  • [Cites] Toxicol Sci. 2007 Nov;100(1):203-14 [17660506.001]
  • (PMID = 20949577.001).
  • [ISSN] 1552-4930
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB009230-03; None / None / / R01 EB000873-01A2; United States / NCI NIH HHS / CA / R21 CA139373-01; United States / NIBIB NIH HHS / EB / R01 EB009230-01A1; United States / NIBIB NIH HHS / EB / R01 EB000873-04; None / None / / R01 EB000873-03; United States / NIBIB NIH HHS / EB / R01 EB000873-01A2; None / None / / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230; None / None / / R01 EB009230-01A1; United States / NCI NIH HHS / CA / R01 CA131164-02; None / None / / R01 EB000873-04; United States / NIBIB NIH HHS / EB / R01 EB000873-02; United States / NIBIB NIH HHS / EB / R01 EB000873-03; None / None / / R01 CA131164-02; None / None / / R01 EB009230-03; United States / NCI NIH HHS / CA / R01 CA131164-04; None / None / / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164-03; None / None / / R21 CA139373-01; United States / NCI NIH HHS / CA / R01CA131164; United States / NIBIB NIH HHS / EB / R01EB009230; None / None / / R01 CA131164-03; United States / NIBIB NIH HHS / EB / R01EB000873; United States / NIBIB NIH HHS / EB / R01 EB000873; United States / NCI NIH HHS / CA / R01 CA131164-01A2; None / None / / R01 EB000873-02; None / None / / R01 CA131164-01A2; United States / NCI NIH HHS / CA / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164; None / None / / R01 CA131164-04; United States / NCI NIH HHS / CA / R21 CA139373; United States / NCI NIH HHS / CA / R21CA139373
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Melanins; 0 / Nanotubes, Carbon; 7440-57-5 / Gold
  • [Other-IDs] NLM/ NIHMS268710; NLM/ PMC3339495
  •  go-up   go-down


31. Howell RC, Schweitzer AD, Casadevall A, Dadachova EA: Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins. Nucl Med Biol; 2008 Apr;35(3):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins.
  • INTRODUCTION: Melanins are high-molecular-weight pigments that are ubiquitous in nature and can also be synthesized in the laboratory from a variety of precursors.
  • Melanins possess numerous interesting physicochemical characteristics, including electromagnetic radiation absorption properties and ability to chelate metals.
  • We have recently reported that melanin has remarkable ionizing-radiation-shielding properties, possibly because it can interact with photons via Compton scattering.
  • We hypothesized that, if administered internally, melanin could play a beneficial role by scavenging various radionuclides, in addition to radiation shielding.
  • METHODS: Three melanins were synthesized from dopamine, 3,4-dihydroxyphenylalanine (l-Dopa) and a combination of l-cysteine and l-Dopa.
  • For control, synthetic melanin made from tyrosine polymerization (Sigma) was used.
  • Melanins were characterized by elemental analysis.
  • The chemosorption of 111In, 225Ac and 213Bi by melanins was studied at 37 degrees C for up to 48 h.
  • RESULTS: The C-to-N molar ratios for dopamine, l-Dopa and tyrosine melanins were very close at 7.92, 8.39 and 8.48, respectively, while in mixed l-cysteine/l-Dopa melanin, that ratio was much lower at 3.63.
  • This mixed melanin also contained 22.33% sulfur, thus confirming incorporation of S-containing motifs into its structure.
  • Dopamine, l-Dopa and tyrosine melanins were very similar in their abilities to decrease the activity of 111In, 225Ac and 213Bi and their radioactive daughters in supernatants by >10-fold in comparison with the starting levels, while mixed l-cysteine/l-Dopa melanin was able to chemosorb only 111In.
  • CONCLUSIONS: We have demonstrated that synthetic melanins made of diverse precursors can chemosorb 111In, 213Bi and 225Ac, with dopamine, l-Dopa and tyrosine melanins being the most efficient towards all three of these radionuclides.
  • Such properties of synthetic melanins can contribute to the development of the novel melanin-based radioprotective materials.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Lett. 2003 Mar 14;220(1):99-104 [12644234.001]
  • [Cites] Anal Biochem. 1985 Feb 1;144(2):527-36 [3993914.001]
  • [Cites] Bioessays. 1992 Jan;14(1):49-56 [1546980.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2420-4 [8698461.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Apr;21(2):192-9 [18426412.001]
  • [Cites] Pigment Cell Res. 2006 Dec;19(6):572-94 [17083485.001]
  • [Cites] PLoS One. 2007;2(5):e457 [17520016.001]
  • [Cites] J Phys Chem B. 2007 Jul 19;111(28):7938-47 [17580858.001]
  • [Cites] Appl Radiat Isot. 2005 May;62(5):667-79 [15763472.001]
  • (PMID = 18355691.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI52733; United States / NIAID NIH HHS / AI / AI060507-04; United States / NIAID NIH HHS / AI / R01 AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-03S1; United States / NIAID NIH HHS / AI / AI60507; United States / NIAID NIH HHS / AI / R01 AI052733; United States / NIAID NIH HHS / AI / R56 AI060507; United States / Howard Hughes Medical Institute / / ; United States / NIAID NIH HHS / AI / AI060507-03S1; United States / NIAID NIH HHS / AI / R01 AI060507; United States / NIAID NIH HHS / AI / AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Melanins; 42HK56048U / Tyrosine; 46627O600J / Levodopa; K848JZ4886 / Cysteine; NIK1K0956U / Actinium; U015TT5I8H / Bismuth; VTD58H1Z2X / Dopamine
  • [Other-IDs] NLM/ NIHMS47415; NLM/ PMC2516407
  •  go-up   go-down


32. Hong H, Sun J, Cai W: Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol; 2008;1:1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomical and molecular imaging of skin cancer.
  • Skin cancer is the most common form of cancer types.
  • It is generally divided into two categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types.
  • Biopsy is still the gold standard for skin cancer evaluation in the clinic.
  • Various anatomical imaging techniques have been used to evaluate different types of skin cancer lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.
  • However, anatomical imaging alone may not be sufficient in guiding skin cancer diagnosis and therapy.
  • Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin cancer imaging.
  • The pathways or molecular targets that have been studied include glucose metabolism, integrin α(v)β(3), melanocortin-1 receptor, high molecular weight melanoma-associated antigen, and several other molecular markers.
  • It is likely that this situation will change in the near future and molecular imaging will truly play an important role in personalized medicine of melanoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53 [9340205.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1770-6 [9586890.001]
  • [Cites] NMR Biomed. 2008 Mar;21(3):296-300 [18246539.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]
  • [Cites] Adv Exp Med Biol. 2008;624:215-26 [18348459.001]
  • [Cites] Adv Exp Med Biol. 2008;624:227-40 [18348460.001]
  • [Cites] Adv Exp Med Biol. 2008;624:296-318 [18348465.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Opt Express. 2002 Jul 29;10(15):707-13 [19451924.001]
  • [Cites] Biotechniques. 2005 Dec;39(6 Suppl):S6-13 [20158503.001]
  • [Cites] J Nucl Med. 1990 Nov;31(11):1831-5 [2230996.001]
  • [Cites] Ann Surg. 1986 Sep;204(3):223-35 [3753057.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:697-715 [8970741.001]
  • [Cites] Dermatol Surg. 1997 Jan;23(1):43-5 [9107293.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]
  • [Cites] Nucl Med Biol. 1999 Aug;26(6):687-93 [10587108.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):147-63 [11005510.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4474-82 [11389078.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):493-8 [11516693.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1847-55 [11752084.001]
  • [Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):913-21 [17146742.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):81-4 [17199571.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):64-72 [17204700.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Cancer Imaging. 2006;6:204-8 [17208677.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Nucl Med. 2007 Mar;48(3):429-36 [17332621.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):765-72 [17348700.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6 [17430375.001]
  • [Cites] Front Biosci. 2007;12:4514-24 [17485393.001]
  • [Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]
  • [Cites] Nucl Med Biol. 2007 May;34(4):363-70 [17499725.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):883-6 [17638732.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]
  • [Cites] Cutis. 2007 Mar;79(3):241-8 [17674590.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] J Radiol. 1998 Apr;79(4):313-7 [9757255.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):662-9 [16704203.001]
  • [Cites] J Dermatol Sci. 2006 Aug;43(2):135-41 [16806842.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2917-23 [10383155.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(4):343-8 [10447583.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):9-25 [10933065.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2674-8 [11352959.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Hybrid Hybridomics. 2001;20(5-6):351-60 [11839253.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):266-72 [12753400.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1279-83 [13679435.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Magn Reson Imaging. 2004 Jul;22(6):843-50 [15234453.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):469-74 [15529179.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):463-71 [17908200.001]
  • [Cites] Dermatology. 2007;215(4):365-72 [17912001.001]
  • [Cites] Panminerva Med. 2007 Sep;49(3):119-38 [17912148.001]
  • [Cites] Nucl Med Biol. 2007 Nov;34(8):945-53 [17998097.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16 [18062745.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):18-25 [18211598.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):329-33 [18215250.001]
  • [Cites] Dermatol Surg. 2008 May;34(5):610-9 [18261097.001]
  • [Cites] Anal Sci. 2008 Feb;24(2):185-92 [18270407.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):196-200 [18300770.001]
  • [Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]
  • [Cites] Clin Nucl Med. 2008 May;33(5):353-5 [18431156.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):37-43 [18486023.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):285-9 [18562760.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s [2297740.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s [2297746.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3445-52 [2334941.001]
  • [Cites] Neoplasma. 1989;36(5):505-11 [2812147.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):329-37 [3346743.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):392-8 [3580508.001]
  • [Cites] Cancer Immunol Immunother. 1987;24(3):221-4 [3594484.001]
  • [Cites] NCI Monogr. 1987;(3):3-9 [3821916.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3378-87 [4005860.001]
  • [Cites] Br J Urol. 1994 Oct;74(4):521-2 [7820438.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):279-85 [7887656.001]
  • [Cites] Int J Cancer. 1994 Sep 1;58(5):749-55 [8077062.001]
  • [Cites] Melanoma Res. 1993 Dec;3(6):395-401 [8161879.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):525-32 [8504043.001]
  • [Cites] Clin Nucl Med. 1997 Jan;22(1):25-9 [8993869.001]
  • [Cites] Nucl Med Biol. 1997 Feb;24(2):171-8 [9089709.001]
  • [Cites] Bioconjug Chem. 1997 May-Jun;8(3):347-53 [9177840.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):638-43 [16546585.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1434-9 [16954550.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2 [17282143.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]
  • [Cites] Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32 [17561215.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707 [17659044.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208 [17846765.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93 [17954911.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42 [18020929.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):101-9 [18202013.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1196-201 [11877745.001]
  • [Cites] Phys Med Biol. 2002 Apr 7;47(7):R67-84 [11996068.001]
  • [Cites] J Med Chem. 2002 Jul 4;45(14):3048-56 [12086490.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):646-53 [12167578.001]
  • [Cites] Phys Med Biol. 2002 Nov 7;47(21):3847-52 [12452576.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):72-8 [12535200.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1210-8 [12902409.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2545-8 [1314697.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]
  • [Cites] Optometry. 2003 Dec;74(12):760-4 [14677727.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9 [14704937.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):677-86 [15099363.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):731-8 [15249335.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1323-7 [15299056.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):458-63 [15304083.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):424-32 [15327550.001]
  • [Cites] Cancer J. 2004 Jul-Aug;10(4):262-70 [15383207.001]
  • [Cites] Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54 [15458273.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]
  • [Cites] Phys Med Biol. 2004 Nov 7;49(21):N363-9 [15584535.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):269-70 [15724029.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):154-9 [15725921.001]
  • [Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]
  • [Cites] Curr Opin Oncol. 1992 Apr;4(2):380-5 [1591311.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]
  • [Cites] Radiology. 1992 Aug;184(2):427-34 [1620841.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054010 [16292970.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):979-85 [16310058.001]
  • [Cites] Arch Dermatol. 2006 Mar;142(3):393; author reply 393 [16549724.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):193-200 [16615102.001]
  • (PMID = 21437135.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3048596
  • [Keywords] NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer
  •  go-up   go-down


33. Belli F, Gallino GF, Lo Vullo S, Mariani L, Poiasina E, Leo E: Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano. Eur J Surg Oncol; 2009 Jul;35(7):757-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano.
  • AIMS: This study describes the experience of the National Cancer Institute of Milano in the treatment of anorectal melanoma over the last 32 years.
  • However, even when a radical surgery was undergone, the prognosis of patients with anal melanoma remains dismal.
  • CONCLUSION: Prognosis of anal melanoma remains poor.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602790.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Soman N, Marsh J, Lanza G, Wickline S: New mechanisms for non-porative ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon nanoparticles. Nanotechnology; 2008 May 7;19(18)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma cells were incubated with nanogold particles and this was followed by insonication with continuous wave ultrasound (2.25 MHz, 5 min, 0.6 MPa).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21494419.001).
  • [ISSN] 1361-6528
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL059865; United States / NHLBI NIH HHS / HL / HL078631-03; United States / NHLBI NIH HHS / HL / HL078631-01; United States / NINDS NIH HHS / NS / R01 NS059302; United States / NCI NIH HHS / CA / U54 CA119342; United States / NCI NIH HHS / CA / U54 CA136398; United States / NHLBI NIH HHS / HL / HL078631-02; United States / NHLBI NIH HHS / HL / R01 HL078631; United States / NCI NIH HHS / CA / CA136398-010003; United States / NINDS NIH HHS / NS / R01 NS059302-01; United States / NINDS NIH HHS / NS / NS059302-02; United States / NCI NIH HHS / CA / CA119342-040001; United States / NHLBI NIH HHS / HL / HL078631-04
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] England
  •  go-up   go-down


35. Sauer CJ, Klaase JM, Gerritsen JJ, Mastboom WJ: [A malignant tumour in the breast is not always primary breast cancer]. Ned Tijdschr Geneeskd; 2005 Apr 2;149(14):729-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A malignant tumour in the breast is not always primary breast cancer].
  • [Transliterated title] Een maligne mammatumor: niet altijd een primair mammacarcinoom.
  • In a 75-year-old woman with a swelling in her left breast, a 39-year-old woman with an anal fissure due to diarrhoea and a 65-year-old woman with chest pain, a mammary tumour was diagnosed that did not originate in mammary tissue.
  • These were a recurrent melanoma, a carcinoma of the thyroid and a B-cell lymphoma, respectively.
  • Breast cancer is one of the most frequently occurring neoplasms in women.
  • Most of these cases concern haematological malignancies and metastases from melanoma and lung cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / secondary. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Melanoma / diagnosis. Melanoma / secondary. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1426; author reply 1426 [15997699.001]
  • (PMID = 15835620.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Kong R, Reddy RK, Bhargava R: Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging. Analyst; 2010 Jul;135(7):1569-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we apply Fourier transform infrared (FT-IR) spectroscopic imaging to examine an engineered tissue model of melanoma.
  • Second, we introduce malignant melanocytes to simulate tumor formation and growth.
  • The development of this analytical approach combining engineered tissue with spectroscopy, imaging and computation will allow for quality control and standardization in tissue engineering and novel scientific insight in cancer progression.
  • [MeSH-major] Melanoma / chemistry. Skin Neoplasms / chemistry. Spectroscopy, Fourier Transform Infrared / methods. Tissue Engineering

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):189-202 [9551650.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2057-9 [8953032.001]
  • [Cites] Arch Dermatol. 1999 Aug;135(8):913-8 [10456339.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Annu Rev Phys Chem. 2005;56:429-74 [15796707.001]
  • [Cites] ScientificWorldJournal. 2005 Mar 18;5:173-82 [15798877.001]
  • [Cites] Nat Biotechnol. 2005 Apr;23(4):469-74 [15793574.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 5;1724(3):262-9 [15935560.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2308s-2311s [16609050.001]
  • [Cites] Biochim Biophys Acta. 2006 Jul;1758(7):923-33 [16730643.001]
  • [Cites] Analyst. 2006 Aug;131(8):875-85 [17028718.001]
  • [Cites] Anal Bioanal Chem. 2007 Mar;387(5):1591-9 [17160382.001]
  • [Cites] Mayo Clin Proc. 2007 Mar;82(3):364-80 [17352373.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:252-8 [17445214.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):044010 [17867814.001]
  • [Cites] Appl Spectrosc. 2009 May;63(5):512-7 [19470207.001]
  • [Cites] Analyst. 2009 Jun;134(6):1208-14 [19475150.001]
  • [Cites] Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S54-8 [19380232.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034011 [19566304.001]
  • [Cites] Tumour Biol. 2009;30(3):109-20 [19440007.001]
  • [Cites] Int J Cancer. 2009 Oct 15;125(8):1796-804 [19569239.001]
  • [Cites] J R Soc Interface. 2010 Feb 6;7(43):229-58 [19864266.001]
  • [Cites] PLoS One. 2009;4(12):e8461 [20041153.001]
  • [Cites] Analyst. 2009 Aug;134(8):1669-74 [20448936.001]
  • [Cites] Anal Bioanal Chem. 2007 Oct;389(4):1155-69 [17786414.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2006;1:2766-9 [17945738.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Analyst. 2008 Feb;133(2):197-205 [18227942.001]
  • [Cites] Analyst. 2008 Mar;133(3):372-8 [18299752.001]
  • [Cites] Dis Markers. 2008;25(6):323-37 [19208950.001]
  • [Cites] J Biophotonics. 2009 Feb;2(1-2):104-13 [19343689.001]
  • [Cites] Anal Chim Acta. 2009 May 29;642(1-2):246-56 [19427483.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1708-12 [11721053.001]
  • [Cites] Regul Toxicol Pharmacol. 2001 Dec;34(3):234-48 [11754528.001]
  • [Cites] J Biomed Opt. 2002 Jan;7(1):148-56 [11818022.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):522-36 [12492494.001]
  • [Cites] J Biomed Opt. 2003 Apr;8(2):185-90 [12683844.001]
  • [Cites] Eur J Cell Biol. 2003 Nov;82(11):539-48 [14703010.001]
  • [Cites] J Control Release. 2004 Jun 18;97(2):269-81 [15196754.001]
  • [Cites] Appl Spectrosc. 2004 Aug;58(8):995-1000 [15324507.001]
  • [Cites] Biochim Biophys Acta. 1995 Jan 25;1270(1):1-6 [7827129.001]
  • [Cites] Anal Chem. 1995 Oct 1;67(19):3377-81 [8686889.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):311-20 [8745328.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):203-10 [9551651.001]
  • (PMID = 20498913.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138882; United States / NCI NIH HHS / CA / R01 CA138882-01A1; United States / NCI NIH HHS / CA / R01CA138882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS259193; NLM/ PMC3030988
  •  go-up   go-down


37. Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL: An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem; 2008 Oct 15;381(2):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many established cancer therapies involve DNA-damaging chemotherapy or radiotherapy.
  • The DNA repair capacity of the tumor represents a common mechanism used by cancer cells to survive DNA-damaging therapy.
  • [MeSH-minor] Animals. Biomarkers / analysis. Clinical Trials as Topic. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Disease Models, Animal. Female. Humans. Melanoma, Experimental / enzymology. Mice. Poly(ADP-ribose) Polymerase Inhibitors

  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674509.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Biomarkers; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 01O4K0631N / veliparib; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


38. Patrick RJ, Fenske NA, Messina JL: Primary mucosal melanoma. J Am Acad Dermatol; 2007 May;56(5):828-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucosal melanoma.
  • The distribution of head and neck, female genital tract, anal/rectal, and urinary tract sites is 55.4%, 18.0%, 23.8%, and 2.8%, respectively.
  • The median age at presentation is the seventh decade, and women are given the diagnosis more frequently than men.
  • [MeSH-major] Genital Neoplasms, Female / diagnosis. Head and Neck Neoplasms / diagnosis. Melanoma / diagnosis. Rectal Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Anus Neoplasms / diagnosis. Female. Humans. Male. Mucous Membrane

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349716.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


39. Kornspan JD, Tarshis M, Rottem S: Invasion of melanoma cells by Mycoplasma hyorhinis: enhancement by protease treatment. Infect Immun; 2010 Feb;78(2):611-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion of melanoma cells by Mycoplasma hyorhinis: enhancement by protease treatment.
  • Mycoplasma hyorhinis (strain MCLD) was recently isolated from a melanoma cell culture.
  • Adherence of M. hyorhinis to melanoma cells followed saturation kinetics.
  • Furthermore, although M. hyorhinis has been considered to remain attached to the surface of the host cells, we show for the first time, qualitatively by confocal laser scanning microscopy and quantitatively by a gentamicin resistance assay, that MCLD is able to invade melanoma cells.
  • Both adherence to and invasion of melanoma cells by M. hyorhinis strain MCLD were dramatically enhanced by mild proteolytic digestion with proteinase K (2.5 microg/mg cell protein for 2.5 min at 37 degrees C) that affected the surface-exposed proteins of this organism, mainly the major 47-kDa lipoprotein.
  • We suggest that the intracellular location of M. hyorhinis strain MCLD is a privileged niche, which may explain the survival of M. hyorhinis in tissue cultures.
  • The enhanced binding to and invasion of melanoma cells by protease treatment may be due to either the activation or the enhanced exposure of an adhesin(s) on the mycoplasmal cell surface.
  • [MeSH-major] Endopeptidase K / metabolism. Melanoma / microbiology. Mycoplasma Infections / enzymology. Mycoplasma hyorhinis / pathogenicity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Microbiol. 1999 Dec;7(12):493-9 [10603485.001]
  • [Cites] Infect Immun. 2008 Dec;76(12):5768-76 [18794296.001]
  • [Cites] Infect Immun. 2000 Jul;68(7):4238-44 [10858241.001]
  • [Cites] Int J Med Microbiol. 2000 Mar;290(1):15-25 [11043978.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):266-9 [11819772.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):417-32 [12663864.001]
  • [Cites] Eur J Immunol. 2004 Jul;34(7):2032-40 [15214051.001]
  • [Cites] Infect Immun. 2004 Sep;72(9):5004-11 [15321992.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochim Biophys Acta. 1980 May 27;604(1):65-90 [6992872.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1604-7 [6257680.001]
  • [Cites] J Biol Stand. 1983 Jul;11(3):247-50 [6885831.001]
  • [Cites] Isr J Med Sci. 1984 Sep;20(9):848-53 [6511362.001]
  • [Cites] J Biol Chem. 1989 Jun 5;264(16):9289-93 [2470754.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jan;26(1):91-6 [2307642.001]
  • [Cites] J Gen Microbiol. 1992 Mar;138(3):407-22 [1593256.001]
  • [Cites] Mol Microbiol. 1992 Aug;6(15):2099-106 [1406251.001]
  • [Cites] Acta Vet Scand. 1994;35(1):93-8 [8209825.001]
  • [Cites] J Clin Microbiol. 1995 Mar;33(3):680-3 [7751376.001]
  • [Cites] Vet Pathol. 1995 Mar;32(2):107-11 [7771049.001]
  • [Cites] FEMS Microbiol Lett. 1995 Oct 15;132(3):189-94 [7590171.001]
  • [Cites] Emerg Infect Dis. 1997 Jan-Mar;3(1):21-32 [9126441.001]
  • [Cites] Infect Immun. 1998 Oct;66(10):4804-10 [9746582.001]
  • [Cites] Ann N Y Acad Sci. 1960 Jan 15;79:433-49 [14400338.001]
  • [Cites] Infect Immun. 2007 Dec;75(12):5716-9 [17938226.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):530-7 [18347140.001]
  • [Cites] FEMS Microbiol Lett. 2008 Oct;287(2):243-9 [18754786.001]
  • [Cites] J Bacteriol. 2000 Mar;182(5):1356-63 [10671459.001]
  • (PMID = 19917715.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.64 / Endopeptidase K
  • [Other-IDs] NLM/ PMC2812198
  •  go-up   go-down


41. Yeh JJ, Weiser MR, Shia J, Hwu WJ: Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol; 2005 Jun;6(6):438-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of stage IV anal mucosal melanoma to chemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925823.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Ye J, Fox SA, Cudic M, Rezler EM, Lauer JL, Fields GB, Terentis AC: Determination of penetratin secondary structure in live cells with Raman microscopy. J Am Chem Soc; 2010 Jan 27;132(3):980-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a first demonstration of principle, penetratin, a 16-residue CPP derived from the Antennapedia homeodomain protein of Drosophila, was measured in single, living melanoma cells.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1992 Apr 8;1120(2):123-43 [1373323.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):361-7 [2070819.001]
  • [Cites] Biochemistry. 1995 Apr 25;34(16):5440-51 [7727402.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):18188-93 [8663410.001]
  • [Cites] Biochim Biophys Acta. 1997 Apr 17;1335(1-2):199-208 [9133657.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] Biochemistry. 1997 Jul 1;36(26):8053-9 [9201953.001]
  • [Cites] Biochemistry. 1998 Apr 21;37(16):5654-65 [9548951.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):84-7 [9695814.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):559-77 [15722164.001]
  • [Cites] Biophys J. 2005 Jun;88(6):4274-88 [15764662.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2166-70 [15928665.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):1233-40 [16272160.001]
  • [Cites] J Pept Sci. 2006 Mar;12(3):233-8 [16161022.001]
  • [Cites] Anal Biochem. 2006 Jun 15;353(2):157-66 [16674909.001]
  • [Cites] Biochemistry. 2006 Jun 20;45(24):7682-92 [16768464.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1775-84 [16940149.001]
  • [Cites] J Am Chem Soc. 2006 Oct 18;128(41):13324-5 [17031922.001]
  • [Cites] Environ Microbiol. 2007 Aug;9(8):1878-89 [17635536.001]
  • [Cites] J Pept Sci. 2008 Apr;14(4):469-76 [18069724.001]
  • [Cites] Mol Pharm. 2008 Mar-Apr;5(2):287-93 [18197626.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 11;371(4):621-5 [18423373.001]
  • [Cites] J Cell Biochem. 2008 Jul 1;104(4):1427-38 [18348254.001]
  • [Cites] J Mol Biol. 2008 Sep 19;381(5):1133-44 [18656895.001]
  • [Cites] J Am Chem Soc. 2008 Oct 15;130(41):13540-1 [18803379.001]
  • [Cites] J Phys Chem B. 2009 Jan 29;113(4):1107-19 [19125640.001]
  • [Cites] Biochemistry. 2009 Jun 2;48(21):4587-95 [19364134.001]
  • [Cites] Curr Opin Cell Biol. 2000 Aug;12(4):400-6 [10873818.001]
  • [Cites] FEBS Lett. 2000 Oct 6;482(3):265-8 [11024473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8 [11087855.001]
  • [Cites] Anal Biochem. 2000 Dec 15;287(2):252-60 [11112271.001]
  • [Cites] J Am Chem Soc. 2001 Aug 15;123(32):7919-20 [11493071.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2437-43 [11711547.001]
  • [Cites] Curr Opin Biotechnol. 2002 Feb;13(1):52-6 [11849958.001]
  • [Cites] J Pept Sci. 2002 Apr;8(4):151-71 [11991205.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 13;1563(1-2):53-63 [12007625.001]
  • [Cites] Biophys J. 2002 Jul;83(1):523-32 [12080139.001]
  • [Cites] Biopolymers. 2003;72(1):1-9 [12400086.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] Biophys Chem. 2003 Mar 25;103(3):271-88 [12727289.001]
  • [Cites] Eur J Biochem. 2003 Jul;270(14):3055-63 [12846839.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):100-7 [12849987.001]
  • [Cites] Biophys J. 2003 Aug;85(2):982-95 [12885645.001]
  • [Cites] J Mol Recognit. 2003 Sep-Oct;16(5):227-33 [14523933.001]
  • [Cites] J Mol Recognit. 2003 Sep-Oct;16(5):272-9 [14523940.001]
  • [Cites] Eur J Biochem. 2004 Mar;271(6):1187-97 [15009197.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12625-35 [14707144.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]
  • [Cites] Analyst. 2004 Oct;129(10):880-5 [15457314.001]
  • [Cites] J Mol Biol. 1970 Jun 14;50(2):509-24 [5476924.001]
  • [Cites] J Mol Biol. 1970 Jul 28;51(2):203-13 [5530393.001]
  • [Cites] J Am Chem Soc. 1974 Jul 24;96(15):4750-2 [4852643.001]
  • [Cites] Methods Enzymol. 1986;130:311-31 [3773738.001]
  • [Cites] Adv Protein Chem. 1986;38:181-364 [3541539.001]
  • [Cites] Int J Pept Protein Res. 1990 Mar;35(3):161-214 [2191922.001]
  • [Cites] Nature. 1990 Sep 20;347(6290):301-3 [2205805.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10444-50 [8144628.001]
  • (PMID = 20041639.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000289; United States / NIGMS NIH HHS / GM / GM073621; United States / NIGMS NIH HHS / GM / S06 GM073621-01; United States / NIGMS NIH HHS / GM / S06 GM073621; United States / NIBIB NIH HHS / EB / R01 EB000289-10; United States / NIBIB NIH HHS / EB / EB000289-10; United States / NIGMS NIH HHS / GM / GM073621-01; United States / NIBIB NIH HHS / EB / EB000289
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / penetratin
  • [Other-IDs] NLM/ NIHMS168012; NLM/ PMC2818876
  •  go-up   go-down


43. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


44. Bonetti M, Gigliarano C, Muliere P: The Gini concentration test for survival data. Lifetime Data Anal; 2009 Dec;15(4):493-518
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Use of the test is illustrated on the classic data arising from the Eastern Cooperative Oncology Group melanoma clinical trial E1690.
  • [MeSH-minor] Clinical Trials as Topic / statistics & numerical data. Melanoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrics. 1989 Sep;45(3):899-904 [2790128.001]
  • [Cites] Biometrics. 1992 Dec;48(4):1223-34 [1290799.001]
  • [Cites] Lifetime Data Anal. 1997;3(1):5-12 [9384622.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12 ):2444-58 [10856105.001]
  • [Cites] Biometrics. 2005 Jun;61(2):403-12 [16011686.001]
  • [Cites] Biometrics. 1992 Mar;48(1):87-99 [1581495.001]
  • [Cites] Stat Med. 1987 Jun;6(4):483-9 [3629049.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2189-94 [18032770.001]
  • (PMID = 19728088.001).
  • [ISSN] 1572-9249
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Di Domenico F, Foppoli C, Blarzino C, Perluigi M, Paolini F, Morici S, Coccia R, Cini C, De Marco F: Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. J Exp Clin Cancer Res; 2009;28:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity.
  • [MeSH-major] Melanoma, Amelanotic / metabolism. Monophenol Monooxygenase / metabolism. Oncogene Proteins, Viral / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Biol. 2000 Jan;203(Pt 1):61-70 [10600674.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3727-32 [10949926.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):184-7 [10901368.001]
  • [Cites] FEBS Lett. 2000 Jul 28;478(1-2):57-60 [10922469.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):197-208 [11139343.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6023-32 [11146554.001]
  • [Cites] Exp Cell Res. 2001 Aug 1;268(1):26-35 [11461115.001]
  • [Cites] J Gen Virol. 2001 Oct;82(Pt 10):2353-62 [11562529.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7866-73 [11753669.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):248-59 [11803468.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Oncol Res. 2002;13(1):3-8 [12201672.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 15;64(10):1503-12 [12417263.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):441-8 [12543800.001]
  • [Cites] Virology. 2003 May 25;310(1):100-8 [12788634.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7971-81 [14634018.001]
  • [Cites] Cell. 1983 May;33(1):153-9 [6678608.001]
  • [Cites] J Immunol Methods. 1986 Nov 20;94(1-2):57-63 [3782817.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6 [2973058.001]
  • [Cites] J Virol. 1989 Oct;63(10):4417-21 [2476573.001]
  • [Cites] J Virol. 1990 Jul;64(7):3226-33 [2161939.001]
  • [Cites] Pigment Cell Res. 1990 Mar-Apr;3(2):49-54 [2117268.001]
  • [Cites] Anal Biochem. 1991 Feb 1;192(2):316-21 [1827963.001]
  • [Cites] J Biol Regul Homeost Agents. 1991 Apr-Jun;5(2):65-70 [1716817.001]
  • [Cites] J Virol. 1991 Dec;65(12):7078-83 [1658398.001]
  • [Cites] Biochemistry. 1993 Apr 20;32(15):3902-6 [8385991.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):806-11 [8496620.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] J Virol. 1993 Oct;67(10):6170-8 [7690419.001]
  • [Cites] Virology. 1994 Aug 15;203(1):73-80 [8030286.001]
  • [Cites] J Virol. 1995 May;69(5):3185-92 [7707548.001]
  • [Cites] J Gen Virol. 1995 May;76 ( Pt 5):1239-45 [7730808.001]
  • [Cites] J Virol. 1995 Dec;69(12):8051-6 [7494320.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1521-3 [9537258.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):76-83 [9633515.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):276-83 [15386416.001]
  • [Cites] J Virol. 2004 Dec;78(24):13613-26 [15564472.001]
  • [Cites] Arch Virol. 2005 Feb;150(2):231-46 [15503216.001]
  • [Cites] Virology. 2005 Feb 5;332(1):102-13 [15661144.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Apr;37(4):852-63 [15694844.001]
  • [Cites] Virology. 2005 Jun 20;337(1):76-84 [15914222.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):543-50 [16867216.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1071-8 [17704805.001]
  • [Cites] Virol J. 2008;5:30 [18302753.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2532-41 [17982485.001]
  • [Cites] Virology. 2000 Jul 5;272(2):315-25 [10873774.001]
  • (PMID = 19133143.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Melanins; 0 / Oncogene Proteins, Viral; 0 / Proton Pump Inhibitors; 0 / RNA, Messenger; 0 / oncogene protein E5, Human papillomavirus type 16; 37491-68-2 / 3,4-dihydroxybenzylamine; 5072-26-4 / Buthionine Sulfoximine; EC 1.14.18.1 / Monophenol Monooxygenase; VTD58H1Z2X / Dopamine
  • [Other-IDs] NLM/ PMC2654431
  •  go-up   go-down


46. Misra UK, Pizzo SV: Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem; 2009 Nov 1;108(4):998-1011
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
  • In this report, we employed the analogue 8-CPT-2-O-Me-cAMP to study binding to EPAC and subsequent activation of B-Raf/ERK and mTOR signaling in human cancer cells.
  • This compound significantly stimulated DNA synthesis, protein synthesis, and cellular proliferation of human 1-LN prostate cancer cells.
  • RNAi directed against EPAC gene expression as well as inhibitors of ERK, PI 3-kinase, and mTOR were employed to further demonstrate the role of these pathways in regulating prostate cancer cell proliferation.
  • These studies were then extended to several other human prostate cancer cell lines and melanoma cells with comparable results.
  • We conclude that B-Raf/ERK and mTOR signaling play an essential role in cAMP-dependent, but PKA-independent, proliferation of cancer cells.


47. Feng Z, Zhao G, Yu L, Gough D, Howell SB: Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol; 2010 Apr;65(5):923-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Efficacy was quantified by delay in tumor growth of NCI H460 human lung cancer, 2008 human ovarian cancer and B16 melanoma xenografts growing in athymic mice following administration of equitoxic doses of PGG-PTX and Abraxane administered on either a single dose or every 7 day schedule.
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / chemistry. Albumins / therapeutic use. Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Line, Tumor. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Mice. Ovarian Neoplasms / drug therapy. Transplantation, Heterologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):642-8 [8913432.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4269-74 [9494519.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):891-7 [10213226.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4523-31 [15542803.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4136-43 [15930349.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):170-6 [16085137.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7794-803 [16172456.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):215-20 [16354318.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1317-24 [16489089.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54 [16609041.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):369-75 [17345004.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1608-13 [18475293.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6):623-30 [18520802.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):728-34 [18594318.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Feb;65(3):515-26 [19593566.001]
  • [Cites] Adv Exp Med Biol. 2003;519:81-99 [12675210.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2829-34 [10914731.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(5):416-22 [11127947.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1590-8 [11527683.001]
  • [Cites] Pharm Res. 2001 Aug;18(8):1157-66 [11587488.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):573-81 [11839679.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):291-7 [14728945.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Nov;13(11):1501-8 [15500397.001]
  • [Cites] Cancer Treat Rep. 1987 Jan;71(1):53-9 [2878719.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5877-81 [7903197.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):600-8 [9466663.001]
  • (PMID = 19685054.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents; 0 / Proteins; 0 / poly(gamma-glutamylglutamine)paclitaxel; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2824123
  •  go-up   go-down


48. Buecher B, Gauthier-Villars M, Desjardins L, Lumbroso-Le Rouic L, Levy C, De Pauw A, Bombled J, Tirapo C, Houdayer C, Bressac-de Paillerets B, Stoppa-Lyonnet D: Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer; 2010 Dec;9(4):663-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
  • Uveal melanoma arises from melanocytes of the uveal tract (iris, ciliary body and choroid) and represents the most common intraocular malignancy in adults.
  • Some rare clinical situations (young age at diagnosis, bilateral or multifocal forms, association with cutaneous malignant melanoma and/or familial aggregations of melanomas) are suggestive of genetic susceptibility.
  • The aim of this study was to evaluate the contribution of CDKN2A/P16INK4A, P14ARF and CDK4 gene germline mutations in a series of patients with uveal melanoma recruited in a single institution with a clinical presentation indicative of genetic predisposition.
  • The contribution of BRCA1/2 gene germline mutations in patients with uveal melanoma and a personal and/or family history of breast/ovarian cancers was also evaluated.
  • These results indicate that the CDKN2A/P16INK4A, P14ARF, CDK4 genes are not responsible for the vast majority of genetic susceptibility to uveal melanoma.
  • They also suggest that one case of uveal melanoma in a family with a history of breast cancer is not sufficient to justify BRCA1/2 genetic testing when the classical criteria for molecular analysis are not present.
  • International studies are ongoing in melanoma-prone families in an attempt to identify uveal melanoma susceptibility loci and genes.
  • [MeSH-major] Cyclin-Dependent Kinase 4 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Genetic Predisposition to Disease. Germ-Line Mutation / genetics. Melanoma / genetics. Tumor Suppressor Protein p14ARF / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Feb;82(4):818-22 [10732752.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):779-83 [10067984.001]
  • [Cites] Int J Cancer. 1999 Jul 30;82(3):325-8 [10399947.001]
  • [Cites] Hum Mutat. 2002 Sep;20(3):218-26 [12203994.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5303-6 [11431374.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):97-9 [8528263.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Feb;44(2):458-62 [12556369.001]
  • [Cites] Ophthalmology. 1996 Feb;103(2):256-62 [8594511.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):42-4 [11857383.001]
  • [Cites] Ophthalmology. 2007 Dec;114(12):2309-15 [17498805.001]
  • [Cites] Genomics. 1999 Dec 15;62(3):369-76 [10644434.001]
  • [Cites] Ophthalmology. 2003 May;110(5):956-61 [12750097.001]
  • [Cites] Am J Hum Genet. 1997 Jul;61(1):120-8 [9245992.001]
  • [Cites] Ophthalmology. 2007 Apr;114(4):774-9 [17207529.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):265-8 [14506702.001]
  • [Cites] Fam Cancer. 2010 Sep;9(3):431-8 [20157784.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9818-28 [17047042.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • [Cites] Virchows Arch. 2008 Mar;452(3):331-6 [18205010.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1377-82 [16174859.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):364-70 [18612309.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18869-74 [9228064.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3817-23 [8033101.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6):768-72 [8970601.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):276-8 [2554754.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Aug;81(4):389-95 [12859267.001]
  • (PMID = 20842456.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p14ARF; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


49. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun; 2009 Jun 05;9:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
  • A differentiation antigen commonly expressed on melanoma cells, gp100 is the target of infiltrating T cells.
  • We conducted a phase I randomized cross-over trial of melanoma patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 microg) every three weeks for three doses.
  • All patients had no evidence of disease; 10 (53%) had stage III disease, 3 each (16%) had stage IIB and IV disease, 2 (11%) had choroidal and 1 (5%) had anal mucosal involvement.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2003 Sep;10(20):1754-65 [12939642.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4 [6933476.001]
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] J Invest Dermatol. 1988 Apr;90(4):459-66 [3280698.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3961-8 [7706734.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 [8610135.001]
  • [Cites] Science. 1996 Jul 19;273(5273):352-4 [8662521.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4749-57 [8840994.001]
  • [Cites] J Immunother. 1997 Jan;20(1):15-25 [9101410.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):350-63 [18200635.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6867-75 [10586088.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • (PMID = 19496531.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01CA33049; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCCIH NIH HHS / AT / P50AT002779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide
  • [Other-IDs] NLM/ NIHMS201057; NLM/ PMC2888533
  •  go-up   go-down


50. Zykova TA, Zhu F, Lu C, Higgins L, Tatsumi Y, Abe Y, Bode AM, Dong Z: Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res; 2006 Dec 1;12(23):6884-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.
  • PURPOSE: Arsenic is a valuable therapeutic tool in cancer treatment.
  • Lymphokine-activated killer T-cell-originated protein kinase (TOPK) is highly expressed in cancer cells, but its specific function is still unknown.
  • We investigated the role of TOPK in arsenic-induced apoptosis in RPMI7951 human melanoma cells.
  • EXPERIMENTAL DESIGN: Expression of TOPK was evaluated in different melanoma cell lines, and liquid chromatography-tandem mass spectrometry analysis was used to identify proteins binding with TOPK.
  • RESULTS: Melanoma cell lines expressing high levels of TOPK were more resistant to arsenite (As(3+))-induced apoptosis.
  • As(3+) treatment induced phosphorylation of TOPK and histone H2AX in RPMI7951 human melanoma cells.
  • Melanoma cell lines with high levels of TOPK are more resistant to As(3+)-induced apoptosis.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2002 Sep;62(3):529-38 [12181429.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3893-903 [12124315.001]
  • [Cites] Science. 2002 May 3;296(5569):922-7 [11934988.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9 [12426127.001]
  • [Cites] Cytokine. 2002 Nov 7;20(3):113-20 [12453469.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):235-42 [12538475.001]
  • [Cites] Genomics. 2003 Feb;81(2):112-25 [12620389.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):967-74 [12771042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8247-52 [12821780.001]
  • [Cites] J Inorg Biochem. 2003 Aug 1;96(2-3):271-8 [12888263.001]
  • [Cites] Cell. 2003 Aug 8;114(3):359-70 [12914700.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):240-5 [14757441.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22747-58 [15028728.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):959-67 [15279782.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45810-4 [15308627.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Hum Pathol. 1984 Dec;15(12):1147-65 [6500548.001]
  • [Cites] Biomed Environ Mass Spectrom. 1988 Oct;16(1-12):99-111 [3072035.001]
  • [Cites] Anal Chem. 1991 Jul 15;63(14):1467-73 [1928722.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]
  • [Cites] Anal Biochem. 1998 Oct 1;263(1):93-101 [9750149.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1041-8 [10070961.001]
  • [Cites] Cell Growth Differ. 1999 Mar;10(3):163-71 [10099830.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):53-63 [15471901.001]
  • [Cites] J Invest Dermatol. 2005 Apr;124(4):807-17 [15816840.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):3931-46 [15987094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62 [16371460.001]
  • [Cites] Leuk Res. 2006 Apr;30(4):437-47 [16171862.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):997-1004 [15541388.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5167-72 [10779557.001]
  • [Cites] Leuk Lymphoma. 2000 Jun;38(1-2):153-63 [10811458.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21525-31 [10781613.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Free Radic Biol Med. 2001 Aug 1;31(3):321-30 [11461769.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Apr;42(1):5-24 [11923065.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47759-62 [11673449.001]
  • [Cites] Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9 [11783945.001]
  • [Cites] Curr Opin Genet Dev. 2002 Apr;12(2):162-9 [11893489.001]
  • (PMID = 17145805.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA111356-01; United States / NCI NIH HHS / CA / CA77646; United States / NCI NIH HHS / CA / CA111536; United States / NCI NIH HHS / CA / R01 CA077646; United States / NCI NIH HHS / CA / R01 CA077646-05; United States / NCI NIH HHS / CA / R01 CA111356; United States / NCI NIH HHS / CA / CA111536-01A1; United States / NCI NIH HHS / CA / R01 CA111536-01A1; United States / NCI NIH HHS / CA / R01 CA111536; United States / NCI NIH HHS / CA / CA111356; United States / NCI NIH HHS / CA / R01 CA111356-01; United States / NCI NIH HHS / CA / CA077646-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / H2AFX protein, human; 0 / Histones; 0 / RNA, Small Interfering; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 2.7.12.2 / PDZ-binding kinase; N5509X556J / arsenite
  • [Other-IDs] NLM/ NIHMS10643; NLM/ PMC2238807
  •  go-up   go-down


51. Giricz O, Lauer-Fields JL, Fields GB: The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem; 2008 Sep 1;380(1):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR.
  • We examined a panel of 26 melanoma and fibroblast samples (tissues and cultured cells) to evaluate the suitability of two commonly used housekeeping genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA (rRNA), for quantitative real-time PCR.
  • Although no overall trends were observed in the expression of the 18S rRNA, GAPDH was up-regulated in melanoma tissue and cultured cells compared with the corresponding normal samples.
  • In melanoma and fibroblast cell lines and tissues, absolute quantification appears to be more appropriate than normalizing messenger RNA (mRNA) expression via GAPDH or 18S rRNA housekeeping genes.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Mol Ther. 2002 Dec;6(6):783-92 [12498774.001]
  • [Cites] Biol Cell. 2004 Oct;96(8):579-94 [15519693.001]
  • [Cites] Nat Med. 2006 Feb;12(2):168-9 [16462795.001]
  • [Cites] BMC Cancer. 2006;6:49 [16515701.001]
  • [Cites] Prostate. 2006 Oct 1;66(14):1521-34 [16921506.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):466-84 [17935490.001]
  • [Cites] Biotechniques. 2008 Apr;44(5):619-26 [18474036.001]
  • [Cites] Arch Dermatol Res. 1999 Dec;291(12):659-61 [10651167.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):17-21 [11476540.001]
  • [Cites] Physiol Genomics. 2001 Dec 21;7(2):95-6 [11773595.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Curr Opin Oncol. 1997 Mar;9(2):178-82 [9161798.001]
  • (PMID = 18554498.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 98799; United States / NIBIB NIH HHS / EB / R01 EB000289; United States / NIBIB NIH HHS / EB / EB 00289; United States / NCI NIH HHS / CA / R01 CA098799-06; United States / NIBIB NIH HHS / EB / EB000289-08; United States / NCI NIH HHS / CA / R01 CA098799; United States / NIBIB NIH HHS / EB / R01 EB000289-08; United States / NCI NIH HHS / CA / CA098799-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Ribosomal, 18S; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  • [Other-IDs] NLM/ NIHMS59889; NLM/ PMC2515093
  •  go-up   go-down


52. Yaramov N, Sokolov M, Angelov K, Petrov B, Pavlov V: [Malignant melanoma of the anus and rectum]. Khirurgiia (Sofiia); 2010;(2-3):5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the anus and rectum].
  • There is approximately 300 cases of malignant melanoma written in the world literature.
  • We write up 13 operated from us for 15 years cases of melanoma of the anus and rectum.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972686.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


53. Hanley KZ, Weiss SW, Logani S: Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis. Diagn Cytopathol; 2009 Jan;37(1):51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis.
  • Fine-needle aspiration (FNA) is a minimally invasive, fast, and accurate diagnostic method for the evaluation of patients with locally recurrent or distant metastases of malignant melanoma.
  • In the vast majority of cases, the diagnosis is straightforward with the characteristic cytologic features well documented in the literature.
  • Divergent differentiation (chondroid, neural, myofibroblastic, and osteocartilagenous) in a melanoma is rare and can potentially create diagnostic challenges if the evaluator is unaware of the same.
  • We report a case of a 46-year-old female with a history of primary anal melanoma who presented with a groin mass.
  • The FNA of the groin mass showed a neoplasm rich in chondroid matrix and raised the possibility of a second primary mesenchymal neoplasm rather than metastasis from the patient's known primary anal melanoma.
  • A review of the histologic features of the anal melanoma showed divergent chondroid differentiation in the anal melanoma with the metastatic deposit in the groin exhibiting extensive chondroid differentiation.
  • [MeSH-major] Anus Neoplasms / pathology. Cartilage / pathology. Inguinal Canal / pathology. Lymph Nodes / pathology. Melanoma / secondary
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973120.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, Mirone P, Masotti G, Moroni F, Tarantini F: Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol; 2005 Sep;25(6):981-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies were performed in several models of FGF-1 secretion (FGF-1 transfected NIH 3T3 cells exposed to heat shock, A375 melanoma cells exposed to serum starvation, growth factor deprived human endothelial cells).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. QUINOLINIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 2005 May;93(3):762-5 [15836634.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7463-73 [11567036.001]
  • [Cites] Anal Biochem. 1988 Aug 1;172(2):518-25 [3189792.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1987-96 [15026334.001]
  • [Cites] J Leukoc Biol. 2000 Aug;68(2):260-6 [10947071.001]
  • [Cites] Neuroscience. 2000;97(2):243-51 [10799756.001]
  • [Cites] J Neurochem. 1992 Dec;59(6):2076-80 [1431895.001]
  • [Cites] J Comp Neurol. 1996 Mar 11;366(3):379-89 [8907353.001]
  • [Cites] J Neurochem. 1989 Apr;52(4):1319-28 [2538568.001]
  • [Cites] Neuroscience. 2001;102(3):687-95 [11226705.001]
  • [Cites] J Neurochem. 2002 Sep;82(6):1465-71 [12354294.001]
  • [Cites] Anal Biochem. 1990 Mar;185(2):363-76 [2339792.001]
  • [Cites] Science. 1983 Jan 21;219(4582):316-8 [6849138.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22209-16 [9712834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10691-5 [1279690.001]
  • [Cites] J Neurochem. 1991 Nov;57(5):1630-5 [1833509.001]
  • [Cites] Oncogene. 1994 May;9(5):1473-7 [8152810.001]
  • [Cites] Adv Cancer Res. 1992;59:115-65 [1381547.001]
  • [Cites] Eur J Neurosci. 2001 Jun;13(11):2141-7 [11422455.001]
  • [Cites] Neurol Res. 2002 Jan;24(1):81-92 [11783758.001]
  • [Cites] Neuroscience. 1994 Jul;61(2):237-43 [7969905.001]
  • [Cites] Pharmacol Rev. 1993 Sep;45(3):309-79 [8248282.001]
  • [Cites] Eur J Pharmacol. 1981 Jul 10;72(4):411-2 [6268428.001]
  • [Cites] J Neurochem. 2002 Apr;81(2):365-78 [12064484.001]
  • [Cites] J Neurotrauma. 1995 Oct;12(5):853-70 [8594213.001]
  • [Cites] Eur J Pharmacol. 1992 Mar 31;213(3):375-80 [1535598.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):748-54 [10605778.001]
  • [Cites] J Cereb Blood Flow Metab. 1999 Jul;19(7):771-7 [10413032.001]
  • [Cites] J Neurochem. 2001 Aug;78(4):842-53 [11520905.001]
  • [Cites] Trends Pharmacol Sci. 2000 Apr;21(4):149-54 [10740291.001]
  • [Cites] Brain Res. 1988 Jun 28;454(1-2):164-9 [3409000.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):87-100 [10443567.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5147-51 [11087725.001]
  • [Cites] Eur J Pharmacol. 1989 Apr 12;163(1):123-6 [2568264.001]
  • [Cites] J Neurochem. 1988 Jul;51(1):177-80 [3379401.001]
  • [Cites] J Neurochem. 1995 Sep;65(3):1176-83 [7643095.001]
  • [Cites] Neuroscience. 1985 Jul;15(3):597-617 [2866466.001]
  • (PMID = 16392031.001).
  • [ISSN] 0272-4340
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Excitatory Amino Acid Antagonists; 104781-85-3 / Fibroblast Growth Factor 1; F6F0HK1URN / Quinolinic Acid; H030S2S85J / Kynurenic Acid
  •  go-up   go-down


55. Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I: Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report. Acta Med Okayama; 2008 Dec;62(6):421-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
  • Anorectal melanoma is a rare malignant tumor with a poor prognosis.
  • In this report, we present a patient with anorectal melanoma who has survived for 9 years after endoscopic mucosal resection.
  • An 85-year-old man was referred to our hospital for further examination and treatment of an anal tumor 2 cm in size.
  • Endoscopic mucosal resection was performed, and the tumor was diagnosed as a malignant melanoma.
  • Although melanoma recurred 4 times thereafter, endoscopic mucosal resection was performed for each recurrent lesion.
  • [MeSH-major] Anal Canal / surgery. Endoscopy / methods. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122689.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Srinivasan N, Bane SM, Ahire SD, Ingle AD, Kalraiya RD: Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J; 2009 May;26(4):445-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3.
  • Metastatic variants of B16 melanoma were chosen to identify specific ligands that mediate lung colonization via galectin-3.
  • Immobilized galectin-3 promoted adhesion of melanoma cells in a metastasis dependent manner.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / metabolism. Galectin 3 / metabolism. Lung Neoplasms / secondary. Melanoma / metabolism. Melanoma / pathology. Oligosaccharides / metabolism. Polysaccharides / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jan;77(1):399-403 [6928631.001]
  • [Cites] Cancer Metastasis Rev. 1988 Jun;7(2):143-88 [3293836.001]
  • [Cites] Methods Enzymol. 1990;182:663-70 [2314261.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):999-1004 [15809094.001]
  • [Cites] Clin Exp Metastasis. 2005;22(1):11-24 [16132574.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):1037-45 [1999484.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1943-50 [16424226.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3805-11 [12839977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8754-8 [7568011.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16717-26 [10358011.001]
  • [Cites] Science. 1987 May 1;236(4801):582-5 [2953071.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):171-81 [18058027.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34 [10580127.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22150-62 [17537730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3577-84 [9042224.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1538-44 [17971775.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Biochim Biophys Acta. 2006 Sep;1760(9):1393-402 [16806716.001]
  • [Cites] Anal Biochem. 1977 Dec;83(2):346-56 [603028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(6):1752-6 [3081900.001]
  • [Cites] Clin Exp Metastasis. 2008;25(4):345-56 [17891505.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1770(9):1427-35 [17600626.001]
  • [Cites] Glycoconj J. 2007 Nov;24(8):411-20 [17457671.001]
  • [Cites] Allergol Int. 2007 Mar;56(1):57-65 [17259811.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3267-71 [7542167.001]
  • [Cites] J Natl Cancer Inst. 1977 Jun;58(6):1867-72 [864765.001]
  • [Cites] J Biol Chem. 1982 Nov 25;257(22):13421-7 [6216250.001]
  • [Cites] Cell. 2007 Apr 6;129(1):123-34 [17418791.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):395-405 [18202191.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):10109-23 [18216021.001]
  • [Cites] Glycobiology. 1999 Mar;9(3):235-41 [10024661.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4851-7 [11406562.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):467-70 [10545492.001]
  • [Cites] Glycoconj J. 1994 Oct;11(5):462-8 [7696849.001]
  • [Cites] Neoplasia. 2005 May;7(5):522-7 [15967104.001]
  • [Cites] Biochemistry. 1993 Jan 12;32(1):260-7 [8418845.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):134-42 [10646865.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65 [12496470.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):29-41 [15630413.001]
  • [Cites] Methods Enzymol. 1990;184:138-60 [2388567.001]
  • [Cites] J Biol Chem. 1986 Aug 5;261(22):10119-26 [3733704.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] J Biol Chem. 1988 Sep 5;263(25):12461-71 [2970459.001]
  • [Cites] Cell Growth Differ. 2001 Dec;12(12):623-30 [11751457.001]
  • [Cites] J Biol Chem. 1987 May 25;262(15):7383-90 [2438278.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2281-7 [7388794.001]
  • (PMID = 18949555.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Benzyl Compounds; 0 / Galectin 3; 0 / Immobilized Proteins; 0 / Oligosaccharides; 0 / Polysaccharides; 3554-90-3 / Thomsen-Friedenreich antigen; 3554-93-6 / benzyl-alpha-N-acetylgalactosamine; 82441-98-3 / poly-N-acetyllactosamine; KM15WK8O5T / Acetylgalactosamine
  •  go-up   go-down


57. Barbus R, Rancea A, Fetica B, Spârchez Z, Kacsó G: Malignant melanoma of the anal canal: a case report. J Contemp Brachytherapy; 2009 Oct;1(3):151-153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal canal: a case report.
  • : This article is one case report of 49 year-old woman diagnosed with malignant melanoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27807457.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; adjuvant brachytherapy / anal melanoma / conservative resection
  •  go-up   go-down


58. Celebi ME, Schaefer G, Iyatomi H, Stoecker WV, Malters JM, Grichnik JM: An improved objective evaluation measure for border detection in dermoscopy images. Skin Res Technol; 2009 Nov;15(4):444-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermoscopy is one of the major imaging modalities used in the diagnosis of melanoma and other pigmented skin lesions.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skin Res Technol. 2002 Nov;8(4):240-9 [12423543.001]
  • [Cites] Skin Res Technol. 2008 Aug;14(3):347-53 [19159382.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):286-91 [7887657.001]
  • [Cites] Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89 [9890182.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Feb;18(2):164-71 [10232673.001]
  • [Cites] Skin Res Technol. 2005 Feb;11(1):17-26 [15691255.001]
  • [Cites] Skin Res Technol. 2005 Aug;11(3):179-84 [15998328.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):183-90 [16567974.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2007 Jun;29(6):929-44 [17431294.001]
  • [Cites] Comput Med Imaging Graph. 2007 Sep;31(6):362-73 [17387001.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):454-62 [17908199.001]
  • [Cites] IEEE Trans Biomed Eng. 2008 Jan;55(1):157-61 [18232357.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Comput Med Imaging Graph. 2008 Oct;32(7):566-79 [18703311.001]
  • [Cites] Comput Med Imaging Graph. 2008 Dec;32(8):670-7 [18804955.001]
  • [Cites] Comput Med Imaging Graph. 2009 Mar;33(2):148-53 [19121917.001]
  • [Cites] J Am Acad Dermatol. 1993 Oct;29(4):581-8 [8408794.001]
  • (PMID = 19832956.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R44 CA060294-02A2; United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / #2R44 CA-101639-02A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS317720; NLM/ PMC3159921
  •  go-up   go-down


59. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R: Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer; 2010;10:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystatin E/M suppresses legumain activity and invasion of human melanoma.
  • In breast cancer, several recent studies have indicated that loss of the cysteine protease inhibitor cystatin E/M leads to increased growth and metastasis.
  • Although cystatin E/M is normally expressed in the skin, its role in cysteine protease regulation and progression of malignant melanoma has not been studied.
  • METHODS: A panel of various non-melanoma and melanoma cell lines was used.
  • Two melanoma cell lines lacking detectable secretion of cystatin E/M were transfected with a cystatin E/M expression plasmid (pCST6), and migration and invasiveness were studied by a Matrigel invasion assay.
  • RESULTS: Cystatin E/M was undetectable in media from all established melanoma cell lines examined, whereas strong immunobands were detected in two of five primary melanoma lines and in two of six lines derived from patients with metastatic disease.
  • Among the four melanoma lines secreting cystatin E/M, the glycosylated form (17 kD) was predominant compared to the non-glycosylated form (14 kD).
  • In the melanoma lines where cystatin E/M was secreted, cystatin C was generally absent or expressed at a very low level.
  • When melanoma cells lacking secretion of cystatin E/M were transfected with pCST6, their intracellular legumain activity was significantly inhibited.
  • Furthermore, invasion was suppressed in cystatin E/M over-expressing melanoma cell lines as measured by the transwell Matrigel assay.
  • CONCLUSIONS: These results suggest that the level of cystatin E/M regulates legumain activity and hence the invasive potential of human melanoma cells.
  • [MeSH-major] Cystatin M / biosynthesis. Cysteine Endopeptidases / biosynthesis. Gene Expression Regulation, Neoplastic. Melanoma / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1626-32 [18754876.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:327-34 [11085925.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):972-82 [11251949.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3493-500 [11309313.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):693-701 [11348457.001]
  • [Cites] Biol Chem. 2001 May;382(5):777-83 [11517930.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 1;1596(1):108-20 [11983426.001]
  • [Cites] Br J Dermatol. 2002 Jul;147(1):87-94 [12100189.001]
  • [Cites] Biol Chem. 2003 Feb;384(2):281-7 [12675521.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2957-64 [12782603.001]
  • [Cites] Oral Oncol. 2003 Sep;39(6):559-68 [12798398.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4069-77 [15205313.001]
  • [Cites] Thromb Haemost. 2004 Jul;92(1):13-22 [15213840.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Histochem Cytochem. 1979 Aug;27(8):1131-9 [90074.001]
  • [Cites] Methods Enzymol. 1981;80 Pt C:535-61 [7043200.001]
  • [Cites] Scand J Clin Lab Invest. 1988 Oct;48(6):573-82 [3064278.001]
  • [Cites] Cancer Metastasis Rev. 1990 Dec;9(4):333-52 [2097084.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15737-44 [8340398.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):301-9 [7519824.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3149-57 [7541714.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Mar;376(3):157-64 [7612192.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):155-61 [7622289.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1996 Jul;114(3):303-11 [8761177.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Feb;377(2):71-86 [8868064.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):682-7 [8938153.001]
  • [Cites] J Biol Chem. 1997 Jan 10;272(2):903-10 [8995380.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):8090-8 [9065484.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):113-23 [9524062.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2733-6 [9661883.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24797-804 [9733783.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):781-90 [10048982.001]
  • [Cites] J Biol Chem. 1999 Jul 2;274(27):19195-203 [10383426.001]
  • [Cites] Anal Biochem. 1999 Sep 10;273(2):278-83 [10469498.001]
  • [Cites] Eur J Cell Biol. 2004 Dec;83(11-12):761-73 [15679120.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2293-9 [15788679.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7066-74 [15905550.001]
  • [Cites] Life Sci. 2006 Jan 18;78(8):898-907 [16150465.001]
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Anal Biochem. 2006 Jun 1;353(1):57-62 [16620747.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15893-9 [16565075.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1233-42 [17043665.001]
  • [Cites] Lab Invest. 2008 Sep;88(9):910-25 [18607344.001]
  • (PMID = 20074384.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / Cystatin M; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cysteine Proteases; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.34 / asparaginylendopeptidase
  • [Other-IDs] NLM/ PMC2822816
  •  go-up   go-down


60. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ: Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res; 2009 May 1;69(9):3918-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Doxorubicin nanoparticles showed 6- to 8-fold lower IC(50) values in P-gp-overexpressing human cancer cells than those of free doxorubicin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Drug Deliv Rev. 2002 Sep 13;54(5):759-79 [12204601.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8 [12111105.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):75-83 [12932639.001]
  • [Cites] J Control Release. 2004 Sep 30;99(2):259-69 [15380635.001]
  • [Cites] J Pharm Sci. 1982 Oct;71(10):1121-5 [6958860.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Biochem J. 1987 May 15;244(1):159-64 [3663110.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1909-15 [1361008.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1771-7 [8083699.001]
  • [Cites] Br J Cancer. 1997;76(2):198-205 [9231919.001]
  • [Cites] Crit Rev Oncog. 1996;7(3-4):227-44 [9258604.001]
  • [Cites] J Immunol Methods. 1997 Oct 27;208(2):151-8 [9433470.001]
  • [Cites] J Control Release. 1998 Jul 31;54(2):223-33 [9724909.001]
  • [Cites] J Control Release. 2005 Jul 20;105(3):269-78 [15939500.001]
  • [Cites] Biotechnol Annu Rev. 2005;11:127-52 [16216776.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81 [16547167.001]
  • [Cites] J Control Release. 2006 May 30;112(3):312-9 [16626835.001]
  • [Cites] Pharm Res. 2006 Jul;23(7):1574-85 [16786442.001]
  • [Cites] Int J Pharm. 2006 Aug 31;320(1-2):150-6 [16713148.001]
  • [Cites] Drug Dev Ind Pharm. 2006 Sep;32(8):973-80 [16954110.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C157-63 [16870828.001]
  • [Cites] Eur J Pharm Biopharm. 2009 May;72(1):9-17 [19111929.001]
  • [Cites] J Biomed Nanotechnol. 2009 Apr;5(2):151-61 [20055093.001]
  • [Cites] Pharm Res. 1999 Nov;16(11):1710-6 [10571276.001]
  • [Cites] J Control Release. 2001 Apr 28;71(3):227-37 [11295216.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):620-8 [11602674.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1987-97 [11747344.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] J Pharm Sci. 2003 Jun;92(6):1250-61 [12761814.001]
  • (PMID = 19383919.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115197-05; United States / NCI NIH HHS / CA / R01 CA115197; United States / NCI NIH HHS / CA / R01 CA115197-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / P-Glycoprotein; 148504-34-1 / calcein AM; 80168379AG / Doxorubicin; 8L70Q75FXE / Adenosine Triphosphate; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS139361; NLM/ PMC2758164
  •  go-up   go-down


61. Balachandra B, Marcus V, Jass JR: Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. Histopathology; 2007 Jan;50(1):163-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist.
  • Poorly differentiated malignancies affecting the anal canal are uncommon but pose diagnostic difficulties because of the wide range of normal cell types that may occur within a limited anatomical region.
  • The range of lesions that may present as poorly differentiated tumours includes squamous cell carcinoma, adenocarcinoma, small and large cell neuroendocrine carcinoma, neuroendocrine carcinoma expressing epithelial cytokeratins and other patterns of mixed differentiation, undifferentiated carcinoma, malignant melanoma, lymphoma and secondary tumours.
  • This review discusses the differential diagnosis of these neoplasms with the aid of short illustrative case studies.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Lymphoma / pathology. Male. Melanoma / pathology. Middle Aged. Pathology, Surgical / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204029.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 72
  •  go-up   go-down


62. Pfefferkorn CM, McGlinchey RP, Lee JC: Effects of pH on aggregation kinetics of the repeat domain of a functional amyloid, Pmel17. Proc Natl Acad Sci U S A; 2010 Dec 14;107(50):21447-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Amyloid / chemistry. Hydrogen-Ion Concentration. Protein Conformation. gp100 Melanoma Antigen / chemistry

  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11266-80 [17303571.001]
  • [Cites] J Biol Chem. 1982 Aug 10;257(15):8738-44 [6807981.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Arch Biochem Biophys. 2008 Jan 1;469(1):100-17 [17588526.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):2307-22 [17991747.001]
  • [Cites] J Alzheimers Dis. 2008 May;13(4):407-19 [18487849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8926-31 [18579777.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13345-50 [18757753.001]
  • [Cites] Q Rev Biophys. 2008 Aug-Nov;41(3-4):265-97 [19079806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19726-31 [19033461.001]
  • [Cites] J Biol Chem. 2009 Jan 23;284(4):2296-306 [19047044.001]
  • [Cites] Biochim Biophys Acta. 2009 Mar;1794(3):375-97 [19071235.001]
  • [Cites] Eur J Biochem. 1987 Aug 3;166(3):705-11 [3111852.001]
  • [Cites] Methods Biochem Anal. 1991;35:127-205 [2002770.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9228-32 [1924386.001]
  • [Cites] Arch Biochem Biophys. 1993 Nov 15;307(1):183-92 [8239655.001]
  • [Cites] Pigment Cell Res. 2005 Oct;18(5):322-36 [16162173.001]
  • [Cites] J Mol Biol. 2005 Oct 21;353(2):357-72 [16171820.001]
  • [Cites] Biochemistry. 2006 Feb 28;45(8):2752-60 [16489768.001]
  • [Cites] PLoS Biol. 2006 Jan;4(1):e6 [16300414.001]
  • [Cites] Annu Rev Biochem. 2006;75:333-66 [16756495.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21198-208 [16682408.001]
  • [Cites] Trends Biochem Sci. 2007 May;32(5):217-24 [17412596.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):4749-53 [18845536.001]
  • [Cites] Science. 2009 Jul 17;325(5938):328-32 [19541956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13731-6 [19666488.001]
  • [Cites] BMB Rep. 2009 Sep 30;42(9):541-51 [19788854.001]
  • [Cites] J Biol Chem. 2009 Dec 18;284(51):35543-55 [19840945.001]
  • [Cites] Arch Biochem Biophys. 2010 Feb 15;494(2):192-7 [19995549.001]
  • [Cites] FASEB J. 2010 Mar;24(3):916-30 [19884326.001]
  • [Cites] Nat Methods. 2010 Mar;7(3):237-42 [20154676.001]
  • [Cites] FASEB J. 2010 May;24(5):1616-29 [20056711.001]
  • [Cites] J Biol Chem. 2010 May 21;285(21):16166-83 [20231267.001]
  • [Cites] J Invest Dermatol. 2000 Oct;115(4):607-13 [10998131.001]
  • [Cites] Pigment Cell Res. 2001 Apr;14(2):86-93 [11310796.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3451-64 [11694580.001]
  • [Cites] Annu Rev Biomed Eng. 2002;4:155-74 [12117755.001]
  • [Cites] J Cell Biol. 2003 May 12;161(3):521-33 [12732614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Dec;71(12):4864-8 [4531026.001]
  • [Cites] Q Rev Biophys. 2006 Feb;39(1):1-55 [16772049.001]
  • (PMID = 21106765.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HL006034-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 8DUH1N11BX / Tryptophan
  • [Other-IDs] NLM/ PMC3003087
  •  go-up   go-down


63. Minichsdorfer C, Hohenegger M: Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. Br J Pharmacol; 2009 Aug;157(7):1278-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
  • In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times.
  • EXPERIMENTAL APPROACH: The human melanoma A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects.
  • CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells.
  • This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-cancer strategies.
  • [MeSH-minor] Atorvastatin Calcium. Autocrine Communication. Caspase 3 / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Cell Line, Tumor. Enzyme Activation. Heptanoic Acids / pharmacology. Humans. Lovastatin / pharmacology. Melanoma. Pyridines / pharmacology. Pyrroles / pharmacology. Simvastatin / pharmacology. Time Factors

  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):483-91 [9816194.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] J Atheroscler Thromb. 2004;11(5):253-64 [15557707.001]
  • [Cites] Melanoma Res. 2005 Apr;15(2):83-9 [15846140.001]
  • [Cites] Cell. 2005 Jun 3;121(5):671-4 [15935754.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Sep;314(3):1032-41 [15914674.001]
  • [Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1127-36 [15889255.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Haematologica. 2006 Apr;91(4):542-5 [16585018.001]
  • [Cites] Dev Cell. 2006 May;10(5):549-61 [16678772.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4808-17 [17001070.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1538-46 [17077356.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1886-97 [17575117.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(17):2580-9 [17950596.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1078-90 [18084615.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] BMC Cancer. 2008;8:9 [18199328.001]
  • [Cites] Melanoma Res. 2008 Apr;18(2):85-94 [18337644.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Curr Opin Pharmacol. 2008 Jun;8(3):333-8 [18243052.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):158-67 [11205904.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):111-8 [12115596.001]
  • [Cites] J Invest Dermatol. 2002 Nov;119(5):1172-6 [12445208.001]
  • [Cites] Surg Clin North Am. 2003 Feb;83(1):109-56 [12691453.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):779-83 [12962723.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43 [15198965.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7 [15198967.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 Feb 1;343(6257):425-30 [1967820.001]
  • [Cites] J Clin Pharmacol. 1990 Dec;30(12):1128-35 [2125605.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3602-9 [1711413.001]
  • [Cites] Br J Pharmacol. 2004 Nov;143(6):715-24 [15289292.001]
  • (PMID = 19563533.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biological Factors; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 48A5M73Z4Q / Atorvastatin Calcium; 9LHU78OQFD / Lovastatin; AGG2FN16EV / Simvastatin; AM91H2KS67 / cerivastatin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC2743847
  •  go-up   go-down


64. Papagiannaros A, Upponi J, Hartner W, Mongayt D, Levchenko T, Torchilin V: Quantum dot loaded immunomicelles for tumor imaging. BMC Med Imaging; 2010 Oct 18;10:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe a tumor-targeted near infrared imaging agent composed of cancer-specific monoclonal anti-nucleosome antibody 2C5, coupled to quantum dot (QD)-containing polymeric micelles, prepared from a polyethylene glycol/phosphatidylethanolamine (PEG-PE) conjugate.
  • A lung pseudometastatic B16F10 melanoma model was developed using tail vein injection.
  • Ex vivo results demonstrated that the agent detects melanoma nodes in a lung pseudometastatic model after a 24 hours wash-out period, while at one hour, only a uniform signal is detected.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nanomedicine. 2009 Jun;5(2):216-24 [19223245.001]
  • [Cites] Int J Nanomedicine. 2009;4:123-31 [19516891.001]
  • [Cites] Mol Pharm. 2009 Mar-Apr;6(2):468-79 [19718800.001]
  • [Cites] Mol Cancer Ther. 2009 Oct;8(10):2861-71 [19825804.001]
  • [Cites] Lasers Med Sci. 2010 Jul;25(4):479-84 [19322625.001]
  • [Cites] Pharm Res. 2011 Feb;28(2):187-99 [20549313.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):044021 [17867825.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205 [16763815.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9929-36 [17047055.001]
  • [Cites] Pharm Res. 2007 Jan;24(1):1-16 [17109211.001]
  • [Cites] J Am Chem Soc. 2007 Jan 24;129(3):482-3 [17226998.001]
  • [Cites] Methods Mol Biol. 2007;374:93-104 [17237532.001]
  • [Cites] Curr Opin Biotechnol. 2007 Feb;18(1):17-25 [17234399.001]
  • [Cites] Nat Med. 2007 Apr;13(4):504-9 [17351626.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4750-5 [11406547.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1759-62 [12459582.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44 [12716967.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] Nat Med. 2004 Sep;10(9):993-8 [15334072.001]
  • [Cites] Oncol Res. 1997;9(8):439-46 [9436197.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):485-90 [9458094.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Cancer Detect Prev. 1998;22(5):470-5 [9727629.001]
  • [Cites] Trends Biotechnol. 2004 Dec;22(12):607-9 [15542145.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] Nat Med. 2005 Jun;11(6):678-82 [15880117.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):73-8 [16138413.001]
  • [Cites] Curr Drug Deliv. 2005 Oct;2(4):319-27 [16305435.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6732-40 [16818648.001]
  • [Cites] Bioconjug Chem. 2006 Jul-Aug;17(4):865-8 [16848390.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):23-8 [17028977.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):024017 [17477732.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] AAPS J. 2007;9(2):E128-47 [17614355.001]
  • [Cites] Br J Surg. 2007 Aug;94(8):996-1001 [17380563.001]
  • [Cites] Int J Nanomedicine. 2006;1(4):473-81 [17722280.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2351-6 [17522707.001]
  • [Cites] Bioconjug Chem. 2007 Sep-Oct;18(5):1391-6 [17630789.001]
  • [Cites] Nat Protoc. 2007;2(10):2383-90 [17947980.001]
  • [Cites] Radiology. 2008 Mar;246(3):734-41 [18223125.001]
  • [Cites] Trends Pharmacol Sci. 2008 Feb;29(2):57-61 [18179828.001]
  • [Cites] J Magn Reson Imaging. 2008 Mar;27(3):574-80 [18219628.001]
  • [Cites] Nat Methods. 2008 May;5(5):397-9 [18425138.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3334-41 [18451160.001]
  • [Cites] Bioconjug Chem. 2008 Jun;19(6):1274-82 [18505278.001]
  • [Cites] J Drug Target. 2008 Jul;16(6):486-93 [18604661.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Sep15;60(12):1421-34 [18541331.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2233-40 [18645032.001]
  • [Cites] Anal Bioanal Chem. 2008 Aug;391(7):2469-95 [18548237.001]
  • [Cites] Biomaterials. 2008 Nov;29(31):4170-6 [18691751.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2138-47 [18709639.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):1991-2006 [18712708.001]
  • [Cites] Small. 2008 Sep;4(9):1406-15 [18711753.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(38):7284-8 [18696519.001]
  • [Cites] Nano Lett. 2008 Sep;8(9):2599-606 [18386933.001]
  • [Cites] Nano Lett. 2008 Sep;8(9):2851-7 [18712930.001]
  • [Cites] Cancer Metastasis Rev. 2008 Dec;27(4):615-30 [18506398.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):754-70 [18834417.001]
  • [Cites] Nano Lett. 2008 Nov;8(11):3834-8 [18928324.001]
  • [Cites] Anal Chem. 2008 Nov 15;80(22):8649-55 [18922019.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):041312 [19021320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19126-31 [19015534.001]
  • [Cites] Anal Bioanal Chem. 2009 Jan;393(2):473-9 [18982314.001]
  • [Cites] Opt Express. 2009 Jan 5;17(1):266-77 [19129896.001]
  • [Cites] Mol Pharm. 2009 Jan-Feb;6(1):246-54 [19049322.001]
  • [Cites] Eur J Pharm Biopharm. 2009 Mar;71(3):431-44 [18977297.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1973-80 [19276264.001]
  • [Cites] Cancer Biol Ther. 2007 Jul;6(7):1136-42 [17611407.001]
  • [Cites] Nano Lett. 2009 May;9(5):2073-6 [19354297.001]
  • (PMID = 20955559.001).
  • [ISSN] 1471-2342
  • [Journal-full-title] BMC medical imaging
  • [ISO-abbreviation] BMC Med Imaging
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB001961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Micelles
  • [Other-IDs] NLM/ PMC2975645
  •  go-up   go-down


65. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]
  • [Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]
  • [Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]
  • [Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]
  • [Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]
  • [Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [